There we go. On that one. There we go. Okay, good morning. Thank you all for joining us, whether you are here in the room or online. It is great to be able to see you all. We have quite a full agenda, so let us get underway. I do want to start with an Acknowledgement of Country. It is a pleasure to acknowledge the Wodi Wodi peoples of the Dharug Nation, who are the traditional custodians of these lands here at Macquarie Park, and we would like to pay respects to elders both past, present, and emerging. Okay, so for the agenda today, we have quite a deep agenda, very much focused on our developed market growth, that being critical to our future. Following me, we have Jan Janssen. Jan has been with Cochlear for over 25 years, been working in cochlear implants for longer than that.
He leads our R&D and is also the visionary behind our product plan and product portfolio, and we are going to go quite deep on that today. Dr. Brian Kaplan leads our clinical group, also a practicing CI surgeon, and will talk today about medicalization and some insights into potential for our technology outside of hearing. Then I will talk to the U.S., and we will have Stu Sayers on APAC and Latin America, Anthony Bishop on EMEA, Europe, Middle East, and Africa. Stu, as many of you know, has been with Cochlear over 10 years now. He started leading our upgrades business, responsible for how do we drive upgrades. We are actually not going to talk about upgrades today, but it is a critical part of our business. He then moved to CFO and then for the last two years been leading Asia Pacific and Latin America.
Anthony Bishop, or AB, just also about 11 years now, a bit over 11 years with Cochlear, about nine of those years leading Asia Pacific and then Latin America, and for the last two years, Europe, Middle East, and Africa. So very broad exposure to the range of markets in which we operate. Karen O'Driscoll is going to talk to the work that we have been doing on our platform, because you know we have been investing in our underlying platforms, getting state-of-the-art systems, platforms, processes, and data infrastructure, which enables us to overlay AI. Karen has been with Cochlear just over three years now and leads our IT and technology from a business system perspective, but also on how do we deliver value from that for the organization. Okay.
At Cochlear, we always like to start with our mission, and it starts with our customers, and then goes to the big problem we are trying to solve, which is that hearing loss, how do we transform the way hearing loss is treated? How do we make hearing loss a medical condition? We will talk to that today, and we will go deep on innovation and the value and potential of our product portfolio. We did put out an announcement this morning that reaffirms our guidance for the year, and I wanted just to briefly reflect back on what happened last year, what we talked about at the full-year result, and how that plays into what we have seen this year. This is very much with a developed market focus, again, that being nearly 80% of our revenue and critical to our long-run growth.
In Western Europe last year, what we saw was a confluence of disruptions across the major markets, combined with some share loss around the launch of Nexa. What we said is we had, and it was one of the worst years we have had in Western Europe because we had so many factors across so many countries. We always see some problems in countries across Western Europe, but normally the portfolio evens itself out. Because of that, we expected that this year we would not see that confluence continue, and we would see some recovery as well as getting share, and certainly that is what we have seen through the first four months of the year. In U.S., the issue was slightly different. We saw strong growth in our DTC, and I will talk a bit to that later.
But then we also saw an impact from consumer confidence and from insurance denials. We talked a lot about that. We rightly got a lot of questions back in April and through the full year on, is consumers' confidence really an issue in terms of healthcare and medical devices, particularly? What we have seen, if you look at some of the Q2 and Q3 reports out of the U.S. from hospitals and from MedTech companies, we are seeing a pretty consistent theme, certainly of insurance denials, and also for some of the MedTech areas, and the most recent of those, and perhaps notable, is Stryker and their Q3 results called out orthopedics with much lower growth than they had seen, and called out insurance denials and the impact on consumers of higher deductibles and cost of living pressures on their propensity to go ahead with surgery right now.
They said, "We think this is a cyclical issue, that people have not gone away, but they are not proceeding to surgery at the same rate." That is a real issue in the U.S. It will take time to resolve. The core of our strategy is to make our business more resilient to that consumer confidence, and that gets to medicalized hearing loss. We will talk to that today. In APAC, we had good performance across the developed countries last year, gained share on the Nexa launches, and have some good momentum there as well. We are holding, reaffirming our guidance. We do have mid-single-digit cochlear implant unit growth across the developed markets through the first four months of the year, and that is certainly pleasing to see it being one of the most critical indicators of performance of the business. Okay, let us go on.
The obvious question coming out of last year is, what is the growth trajectory from here? You can see through 2016-2025, 8% compound annual growth in revenue, 9% compound growth in profit. In 2026, 1% down in revenue, 22% down in profit. Certainly, that is that slower growth conditions. It is part FX, but the obvious question that you are asking is, what is going to happen from here? We have confidence in our plans to drive growth over time. What we want to talk through today is how do our growth plans and our technology plans drive that growth? Why do we have confidence, and what are we looking for as we go along the way that give us indicators that confidence is well justified? The starting point of thinking about our growth is the opportunity.
The key thing that has not changed in the last year is the opportunity for our products, the clinical need is actually bigger than it was 12 months ago. As we talked quite a lot about, hearing loss is a highly prevalent medical condition, and it is actually undertreated at every level of hearing aids. It is true for hearing loss. It is true for hearing aids as well as hearing implants that there is a low penetration. Why is that? That is the case because it is not seen as a medical condition. When it is not seen as a medical condition, then we have these ad hoc care pathways. The core of our strategy for growth, technology aside, is how do we medicalize hearing loss, particularly severe to profound hearing loss, and how do we build those consistent growth pathways?
You will hear from AB and Stu and from me as I talk to the U.S. about the work we are doing to build that out. From Brian overall, you are going to hear what is the overarching plan on medicalization of hearing loss. This is a long-run plan that builds the infrastructure and ability to drive those referrals. Part of medicalizing hearing loss and getting this more consistent referrals is to really understand what are the barriers on the patient journey to people getting an implant, and how does our strategy address those barriers?
There is a range of barriers here, which we have talked about over time. Low awareness. I am going to talk as we go a little bit more about these rather than trying to keep a high-level summary here. Low awareness, access barriers. Hearing loss is still stigmatized. People do not want to wear a hearing aid. They do not want to wear a sound processor when they see a sound processor is bigger than a hearing aid. That stops a number of people from proceeding on the journey. People do not want to have surgery.
They want to have surgery only if they believe there is a real upside and there is a significant downside from not having it. We need to make the evidence is there that supports why you would want to get your hearing loss treated. It is not necessarily well adopted. Concerns about losing residual hearing. Many candidates for cochlear implants these days now have a level of hearing. It is a low level of hearing. It is not very functional, but they absolutely rely on it. The risk of losing it also causes hesitation on that. We will talk about what we are doing there. Then there is variability in outcomes.
That is true for hearing aids as well as it is for hearing implants. That variability is not a function of the technology. It is actually much more a function of the anatomy, but it has not been predictable, and it has not been able to be measured. We now believe we can do that, which will help in that counseling, because what variability outcomes means is less confident counseling, which also does not help people get on that journey. Finally, aftercare. Aftercare is not so much a barrier, but it uses up healthcare system capacity, which takes capacity away from the front end, where we want to expand access. Today, we are going to talk through how do we expand that access to treatment? What are the growth strategies there? The role of technology.
How do we shape the implant category, given the weight of our spend and the way we are advancing our technology? How does that support our growth into the future as well as our competitive advantage? How do we think that we can actually transform the care model to create capacity up front? Given the investment that we are making in our underlying platforms and the potential of AI, we are very confident now we are right on the right path and already seeing benefits to realize operating leverage so that we can fund the growth, but also to actually enable our growth through the technology, and we will talk to that. When we map those strategies across these barriers, they address each one of them. The critical issue for us is really thinking about our resource allocation over time.
We do not want to just invest in each of them and slowly move down every barrier at once. We do have a portfolio, and we have got to think carefully, and we do think carefully about where is the opportunity to go faster now, to get results now, and where do we invest to make sure that we are building the platform for future growth with some of the longer-run things, which are some of the aspects of medicalization. Now I am just going to step briefly through each of those four areas I talked about and more set up the why are they important and how do we think about them. The detail of what we are doing will come in the following presentations. If we start with expanding access to treatment, this gets to the front end of the barriers about awareness and about access.
What we know right across the world, and we have talked about this a lot, is that the penetration of cochlear implants for adults and seniors is very low. It varies, Australia leads, but leading at 8% is hardly something to be too proud of, but it is insightful, and you will hear from Stu on this, of what do we then learn to take to other countries. If we contrast this with children, where the uptake for children where cochlear implants is the standard of care, we are then at over 80% penetration. If you go back, and I will talk about this a bit later too, for people with severe to profound hearing loss, 80% of them do have hearing aids.
80% of them know they have got a hearing loss and they take action, but the path is not there to get them to a cochlear implant, which in virtually all of their cases is clearly a much better solution in terms of outcomes. What do we need to work out to dig into those barriers a little bit further? It is about the recognition of the need to treat and how to refer, and we will talk to that later. Access to treatment, which can be funding. Some markets are well-funded, but others still have constraints. It can be the number of clinics or access to a clinic, geographic distribution of clinics, operating theater capacity, for example. Then there is the individual's motivation to act. Is my hearing loss serious enough condition for me to go and get surgery?
There are three areas we work on to expand, to build up, to take down those barriers at the front end of that journey. We have made pretty good progress at doing that over time. We have seen 9% growth in the adults and seniors in developed markets over the 10 years there. But it was zero last year, and we know about that. We have talked about that, and that is where you have to get under, why was it zero last year? We talked up front about some of those conditions. What does our strategy do to address those conditions? Not only to drive that underlying growth that we had through 2025, but how to make our growth more resilient to the economic conditions we have. The critical piece to that is getting stronger referrals. We talked about this at the full year result.
Where there are stronger referrals, we do see more consistent growth rates. This is example for the U.S., which again, I will talk about in a little bit more depth later. But where we are engaged in helping people on the path, we continue to see strong growth. Where a clinic has a network around them that pulls people in, we continue to see growth there despite economic conditions. Where there is not that help and infrastructure last year, because there were not those referral paths, we saw no growth. Actually, we saw a slight decline in that growth. That is the problem we need to solve, and that is because, and we will talk to it, the extent people are getting referrals in that area, they are very soft referrals.
You could think about a cochlear implant, or a cochlear implant might be an option for you, versus a strong referral, which is, you are a candidate for a cochlear implant, here is where you go to get one. This is what you might be able to expect in terms of outcomes, and this is the consequences if you do not go ahead, or the potential consequences. That is what we do when we help people along the journey. The soft referrals is what cause people to drop out, if they even get it. Many do not even get the soft referral. To be able to drive those referrals and build the referrals, we need the evidence, we need the clinical practice guidelines, we need policy support, and all of that leads to behavioral change. That is the core of medicalization. Brian is going to talk to this later.
It takes time to do, and we are not waiting till we have hearing loss medicalized, but recognizing it is a long path to get there, but along the way, we can make progress. At less than 5% penetration, we do not need to solve it straight away. We need to make sure that we are making consistent progress. Onto the shaping the implant category and our technology. We are a technology company. The technology is the core of the opportunity that we have in front of us. The technology is the core of our competitive advantage. The reason that we have the market position we have is because of the technology that we have built over time, the system we have built over time, and that we advance every part of the system. Because it is every part of the system that actually delivers the hearing outcome.
Our scale enables us to do that. Our competitors don't have that scale, and they have to choose components of the system to advance, which they do, and then they market well. By advancing the whole system, it gives us a moat which underpins our competitive advantage. That's been the 40-year history of building our advantage through scale. What Nexa does is it gives us two things. First of all, Nexa is the platform for DE E and for TIKI. It enables us to develop these follow-on implants with significant potential, but from a really strong base.
That was one of the most critical elements of the Nexa launch, is to see the reliability of the Nexa platform. As we now do things like enhance the platform, that applies to DEE and TIKI. As we reduce costs on Nexa, that will flow through to DEE and to TIKI. The other thing that Nexa does is it enables us to not only, through the platform, have follow-on implants that benefit, but actually advance the whole system. The power management in Nexa enables us to shrink the externals more than we would without it. The diagnostics that are in Nexa provide information that enable our Connected Care solutions to be more automated, more streamlined, and provide more data to our clinicians to give them confidence in the performance of their patients.
The Nexa core brings another element to our competitive advantage, which is we can now not just advance the system through the weight of money, but through the weight of the technology. We can advance the whole system in a way that our competitors actually can't do because they don't have the core smart implant technology to enable them to shrink the processor or automate more of the Connected Care. It brings another dimension to our competitive advantage, is the core electronics that sit in Nexa. Our technology doesn't just support competitive advantage, it also is a key part of how we drive growth. Jan's going to talk in depth about how we build the technology up over time, what we're doing in each of these areas. I want to talk to the portfolio expansion part here.
Because what we get from more than AUD 3 billion in R&D is not just a great Nexa system with potential for TIKI, but we do have a whole range of technology capabilities and capabilities in the company around developing and commercializing technology. When we look at the system we've got now with Nexa, we have, we would say, probably one of the most sophisticated head-based neural stimulators of any company in the world. We know how to get value from that in hearing. We have, as we've talked about over the last eight or nine years, talked about how do we get value, is there opportunity to get value from that outside of hearing? We've got to be very careful on that. We've got to think about the opportunity, but we have been exploring in a few different areas.
One of those is a vestibular implant, and Brian is going to talk to that later. It's an early stage feasibility study, but an interesting extension. But within hearing, that portfolio expansion also applies. The Osia implant launched in 2019 is a new category. It overlaps with the Baha category, but it is a new category. And seven years on, we're seeing the growth in Osia. We've done work to get reimbursement to build out the category, and the Osia implant's one of the fastest growing parts of our business. TIKI is the other element of portfolio expansion. I want to talk to TIKI because that fully implantable technology is enormous opportunity for us to drive growth. We can see through our market research that people are more interested in a TIKI than a conventional implant.
We see that in the rate at which our clinical studies have recruited, that there is demand for a TIKI. Why is that? First of all, why is that, or what's the product got to do? It's got to give a better hearing outcome than a high-powered hearing aid. It's got to be equivalent, at least, to a current cochlear implant system. It gives people freedom, not have to put a hearing aid or a sound processor on and off and still be able to hear. That gives people confidence and control over their hearing, and that broadens the opportunity. But having a product that is more attractive to the consumer isn't enough in a healthcare system to get adoption. What we've been working very hard on is not just having the right technology, and we're going to talk to that, but making sure it fits within the healthcare systems.
That means it needs to fit broadly within the funding constraints that there are in healthcare systems. It needs to fit within operating theater, surgical capacity constraints. It can't take much longer surgery, for example. It needs to fit in an environment where there is constrained aftercare. The programming, the mapping of the system can't be significantly different than an existing CI, and in future should be even more automated. As we think about TIKI, we're not just thinking about, this is a great piece of technology, but we're thinking about how do we build a fantastic piece of technology, but integrate it into healthcare systems in a way that gets mass market adoption. That's the whole point of a TIKI implant, is to open up and to drive growth.
We've talked about where we are in the process in terms of having clinical studies for pivotal studies, regulatory approval underway. Jan will talk further about the technology and how we've developed and how we've thought about this technology, and how we've learned over time to get what we think is now the right system to bring to market, subject to regulatory approval. Okay. And then, clicked and it didn't work. There we go. Transforming the care model. I'll go briefly over this, but we've talked about this a lot over time. There aren't enough audiologists in the world to serve the people with hearing loss. Therefore, how does not just us, but also hearing aid companies think about maximizing their time on the most valuable things they can do? And that's on evaluation.
That is on determining the right level of care for people, not necessarily intervening to provide that care once that choice is done, because that can be automated, and with evidence it can show actually what is the optimum level of intervention. What we have already been able to show, not we have been able to show, it is actually the industry has been able to show, is that we can reduce what was the- Going back the sort of traditional way of treating adults down to less than a third. With technology, there is the opportunity to go further than that. Then finally, scaling growth with technology and AI. We have, over the last six years, invested considerably in replacing our core systems. We needed to do that in part from a stay in business. You have got to replace core systems now and again.
But we have also taken the approach of how do we use this to get leverage. Standardized systems around the world, standardizing processes, standardizing the data architecture. That then enables us not only to get leverage from the functionality of the systems, but also significant potential with artificial intelligence to get more benefits than we had thought originally. Karen is going to talk more about how we are doing that. We are seeing benefits already, as we should be, given the rate of advance of technology. Okay, so let me finish with a summary of what do we want to do? How will this impact on our financial performance? We have clear ambition to grow our net profit by 10% per annum. We talked about how our margin was down at the end of last year.
We see that path getting back that margin back to 18% while we build the revenue growth over time. We want to have a strong dividend and make sure that we keep the balance sheet conservative as we do that, given this is a relatively high-risk business. So having flexibility in the balance sheet is important so we can take risk in how we bring our technology about. But then it is driving growth through the medicalization and streamlining care, expanding the market with new technology. TIKI, we will talk a lot about, but there is potential value beyond there. Then getting that operating leverage, not just to drive growth, but also with technology to enable growth. Okay, so with that, I am going to hand over to Jan Janssen, who is our Chief Technology Officer, to talk through how we approach technology. Thanks, Jan.
Thank you, Dig, and thank you all for joining this morning. It is a great opportunity to share with you some of our philosophy and progress, and give you some deeper insights of the technology that we are developing. Particularly, as we think about how technology can do things at the same time. First of all, we do see that technology plays a very important role in helping every individual to achieve their full potential. There is still a lot of opportunities I will share with you in how our technology, particularly Nexa, is going to do that. But as we heard from Dig, and as I am sure all of you know, there is this huge unmet need, and we do see technology has this fantastic opportunity to get many more people into the care pathway and benefiting from a much more effective hearing solution than a hearing aid.
A concept that can be sometimes a bit helpful to see a bit where we are is this concept by Crossing the Chasm by Geoffrey Moore. It was not developed in the first place for medical devices. Nevertheless, I think it is an interesting concept that says you have an early market, then there is a bit of a gap that you need to overcome before it becomes mainstream. It is interesting if we look back over the last 30 years, we actually have been able to cross that chasm for pediatric patients. As you saw from Dig, we have over 80% of children in developed markets and now also in some of the emerging markets have been able to make that step. For adults, it is a different story.
We have been able to move the needle a little bit, and Australia is so far the best example. Not a great example yet, but 8%. There is more that we need to do to help people cross that chasm. The thing is that the concept there is that the expectation is actually different for those early adopters, those pioneers, versus the mainstream. That is really, as we think about technology, as we think about then the different elements or aspects that people consider in this pathway, there we see a different trade-off that parents are making for their children versus adults and seniors. Things like the preservation of residual hearing is hardly a consideration for parents because first of all, these children have very little residual hearing, and the benefit to participate in mainstream education is so big by going to Cochlear implant.
Whereas adults and seniors, they typically would have gotten that hearing loss over time, gotten used to it. So you see that there is a different kind of trade-off, and that is really where technology, we believe, can play a very important role. To address these hurdles that we have, such as preservation of residual hearing or variability of outcomes, or making the externals a lot more attractive, does require significant technology breakthroughs. As we see in other areas of technology in society, these breakthroughs, these technologies, even the advent of landline telephones was in itself a big breakthrough, by the time it got there. It was built on many other smaller inventions that need to happen. Someone had to invent the microphone before we could think of a telephone. Then, of course, we started with landline telephones. We saw the first cordless phones.
We got to cell phones in the 1990s. But when it really became transformational is when also the things in the environment changed. Not only the phone technology changed, the internet appeared, cloud technology appeared, Wi-Fi appeared. It is when all these things came together that suddenly we find ourselves with the iPhone and a truly transformational product. That is really what we are That metaphor is also the way that we think about our technology in the area of implantable hearing. Because each of these innovations that you see here, Nexa, DEE, and TIKI, in themselves, often are built on 20+ years of hard research and technology development. Each of those we started well at the start of the 2000s, some of them even before. What is also interesting is you look at these three technologies on the left-hand side, they all relate to the implanted component.
Dig spoke about the competitive advantage that we have through our technology. Doing things in the implant is a lot harder than doing things on the external side. You can see, it will be interesting to see how many companies can actually follow that step to the step changes in the implant technology, because that's really where the benefits, the customer benefits will come from. That will help us to drive better outcomes. Drug-eluting electrodes will help to protect that residual hearing, and TIKI will provide a different wearing option for people that we think will be very attractive. That's also what the market research indicates for people to make that step from a high-power hearing aid to a cochlear implant.
But it's not only these things individually, you add them up, and as Dig already alluded to, these technologies also form the foundation to shrink the externals further quite a lot in the future, as well as streamline the care pathway. That's really what our goal is with these technologies, is to help to make the technology much better meet the expectations of adults and seniors that today are wearing a high-power hearing aid, so that we can effectively do the same as what we have been able to do in the pediatric market, is make the cochlear implants and implantable hearing technology the mainstream solution. Of course, that has to go together with the medicalization of hearing loss.
It is a medical intervention, but you see we're coming from these at two angles, making the solution much more attractive, as well as creating the necessity for treatment. Today, the way that we go about developing these technologies and the way we've structured the presentation. First, go a bit deeper in what are we doing to further drive these hearing outcomes, make them more predictable? How does the TIKI technology will give people a lot more freedom living their life with an implantable device? How can we use technology to streamline that aftercare? I also will build a bit further onto what Dig mentioned in how we can leverage our technology platforms in areas that are adjacent to our current technology. When we talk about hearing and hearing outcomes, first it's probably worth my mentioning that hearing outcomes comprise a lot of things.
It's not just about a speech test in a sound booth where people listen to in a quiet environment. It's really about the real-world outcomes. It's things like music perception, it's things like listening effort, directionality. Hearing in noise remains a significant issue. We have to acknowledge today that there is still a significant gap between normal hearing and hearing with a cochlear implant. Cochlear implant is a lot better than a hearing aid, but by no means it gives you back normal hearing. As you're considering to go through surgery, you're like, "N ot so sure whether how good it's going to work, and particularly how good it's going to work for me as an individual." Because on the right-hand side, you can see there, 95% of people who get a cochlear implant do better than with a hearing aid. But that's at group level.
At an individual level, it is much harder to predict that. Of course, people make the decision for themselves, not for the entire group. As we think about how we can deploy technology then to improve a lot of these hearing outcomes, I will do a bit of a one-on-one what a cochlear implant system actually does here. A cochlear implant has to capture the sound. If you would have a cochlear implant today, the microphones in the process will capture the sound. That is one way the sound will get in, or the sound comes in through streaming, through the smartphone connectivity that we have. We can clean up that sound with our front-end processing, and we can have the other pathway there through the wireless connectivity, in which Cochlear has been the leader and we continue to be the leader in that.
It goes into this kind of black box of what the actual core functionality of a cochlear implant is. At the end, there is the electrode array. That is the part that delivers the electrical stimulation to the nerve, and from there, it goes to the brain. As we think what can we do to further improve and what are we doing to further improve, a very exciting opportunity that we are advancing very quickly now is the use of AI, of deep neural networks for enhanced noise cancellation, because we know that is one of the biggest areas of concern for people with hearing loss and also with cochlear implants. The advent of deep neural networks is giving us another opportunity to improve that.
We already have very powerful and best-in-class algorithms that are good in spatial noise suppression, so they will suppress noise sources around you with our Beam, Zoom, ForwardFocus technology. With AI, we can give this another significant boost. Very exciting technology we have in the pipeline for that. Also, the wireless connectivity keeps evolving. A few years ago, a new Bluetooth standard got ratified. It is called Bluetooth Low Energy Audio. This is technology that is not just for people with hearing loss. This is technology that will appear in every computer, in every television, and very excitingly, it also has a broadcast function. The Sydney Opera House is one of the first places in the world that already has installed this.
If you have a hearing aid today that is Auracast compatible, you could go to the Opera House and get the sound straight into your hearing aid. That technology, we are also now bringing into the world of cochlear implants. We have far progressed through that development. It is not completely yet ready for prime time, but you can see how these technologies can really complement the other things we do to help people to navigate through their life. What you see on the right-hand side there is a screenshot of something that will look very similar to what you get if you walk into a building that says, "Three Wi-Fi access point available." In the future, you will get something like that for audio, and you can say, "Okay, I am in an airport.
I want to listen to the announcement of gate 45, and seamlessly can continue to stream from your phone, listen to Spotify. It will automatically switch over when there's a gate announcement. Things like that, very exciting. Technology, it will take a few years to roll that out, but Cochlear has been and continues to be on the forefront of that wireless connectivity. As we then think about other elements of hearing outcomes, such as appreciating music, listening effort, sound quality, hearing in noise, we also have to turn our attention to the actual core of a cochlear implant system. I won't bore you with the technical details in there, but there is a particular part that we're going to talk a lot about today, which is that last part, which is the actual generation of the electrical stimulation and the electrodes that then makes that connection with the nerve.
That's what we call the electro-neural interface. You're going to hear that word a lot, because that is what we, over the years, we convinced that that really holds the key to further unlock hearing performance. It's also the reason why we developed the Nexa implant. Of course, when we launched the Nexa implant, we launched it as the world's first and only smart implant, and it's great that it's a smart implant that has fantastic capability on board to be upgraded and evolve. But the core rationale behind Nexa is to drive better hearing outcomes.
It has not only the ability to store maps in the implant, to have onboard diagnostics, better RF connection, but it has unique capabilities in terms of signal processing that we brought into the implant, because that will be important, necessary to deliver some of these new sound coding strategies, but also because the NEXOS chipset in Nexa is also the basis for our TIKI implant, where we also need signal processing in there. Nexa has unprecedented stimulation flexibility. This flexibility is not clinically available today. We're going through that research, and I'll share some of these early results with you. But that's really our vision for Nexa that we had at the time of launch.
When we launched the products, we didn't want to say, "Look, this is something that will create great opportunities for the future." It's also important that it has here and now benefits. It is ready for the future through the fact that it's firmware upgradable, as every product nowadays, I think, should be. Like I said, this platform will be used for TIKI, so our TIKI also will be firmware upgradable. Because we worked on that power link, it has the world's smallest processor with all-day battery life, and it already helps with care, because now with Nexa, if your processor breaks down, you don't have to visit the clinic. We can send you a blank sound processor. You put it on, the map is in the implant, it coordinates, it syncs it back, and again, we get you back on air without demanding any audiology time.
Because like Dig said, it is a big bottleneck, and we want to take all of that, not really value at a time, out of the hands of the other professional. I later have another example how the ability to store information in the implant is already also been used in how people actually been switched on as they receive a cochlear implant. I spoke about the fact that with Nexa, we've been able to deliver the smallest sound processor in the market. What we're also seeing with Nexa is people using their device for longer. Here on the left-hand side, you see here different age groups. The two in the middle is 6- 18 and 19- 65. We see people using up to 40 minutes, 50 minutes longer device use per day. We don't really know why.
We don't really have hard evidence why it is. The most logical connection we can make is the fact it's a smaller sound processor, much more comfortable to wear. This is not just a convenience thing. We also know that daily CI use correlates with outcomes. The more you use your sound processor, the better you'll hear. You can see how some of these things really start to build on each other. But like I said, the real rationale behind Nexa was how can we use technology to deliver a better hearing outcome, in particular, how we can improve that neural interface. That's where the new stimulation capabilities from Nexa come in. Monopolar stimulation is something that all implants have today. This focused stimulation is really unique to Cochlear's Nexa. With that smartness that we have, we can do a number of things.
We can improve surgical feedback. We can develop precision diagnostics for neural health, and I'll show in a moment what we're doing there. We are working, or with that, we can conceptualize new ways to stimulate that hearing nerve. Like I said, it's a lot around this electro-neural interface. It's really where the rubber hits the road, if you want, between the device and the body. This is an area that we've been working on for many years. In fact, our philosophy to have 22 channels in our device, not 12, not 16, was already with the awareness that in normal hearing, we have the so-called 24 critical bands.
At the time, Cochlear could get already to 22 electrodes, thinking how this natural hearing works, and using that choice of 22 channels to really get as close as possible to how the body works for normal hearing. It started there. In the 2000s, we went to perimodiolar electrodes, again with the idea if we can deliver the electrical stimulation closer to the nerve, we get a more intimate connection and higher precision. With Nexa, we can really start to put these things together, because once you have 22 channels, a well-placed perimodiolar electrodes, and a smart implant with focused stimulation, then you can start thinking of different ways to use this capability for both diagnostics purposes, but also for day-to-day listening situations. That's what we'll go into a bit deeper today.
If we unpack what the device needs to do from an electrode neural interface, the first thing is you want to protect what is there. Secondly, you want then to make sure that you create the best possible connection between the electrodes and the nerve. That is where we have evolved our perimodiolar electrodes over the years, so that it has become a very atraumatic device that is placed close to the nerve. For those of you that have been to these meetings before, you know that perimodiolar electrodes are an absolute differentiator for Cochlear. It is great to see that there is more and more independent research that is also coming out to demonstrate the superiority of perimodiolar electrodes.
Last year, a meta-analysis came out, study by Duckett et al, published in 2025, that looked at 92 studies, over 5,000 patients, and they compared how a patient is doing that got a pre-curved electrode, so a perimodiolar electrode versus lateral wall electrode. What they found is that over these 5,000 patients across all brands, that those with a perimodiolar electrode got 47% improvement- pre to post, so with a hearing aid to the cochlear implant.
Those with the lateral wall electrode only got 36% improvement. I think if this is not the proof, I do not know what the proof will be. It is done independent from Cochlear, over 5,000 patients. So I think this is very hard to refute. But of course, we can do more than that. So protect what is there, getting the best electrode, but then we know there is this factor of understanding the individual ear's anatomy.
It is not just the anatomy in terms of the size of the cochlea. Some of our competitors make a lot about the importance of the size of the cochlear electrode length. Plays a bit of a role. There is the hearing history, but what we have learned over the last 10 years or so, what really makes the huge element that makes a big difference in how people perform with a cochlear implant is what we call the neural health. How good is that hearing nerve that the cochlear implant is triggering with electrical stimulation? What we know today is, what we learned over the years, is that neural health can explain up to 50% of outcome variability. Sometimes clinicians will tell us that patients that are same age, same audiogram, same gender, one does really well, the other does not well at all.
What is happening is that we know that every person that actually needs a cochlear implant has moderate or severe or profound hearing loss. That means that hearing nerve is not a fully healthy hearing nerve as a normal hearing person. We can still stimulate it, but it is not fully patterned. We also know from research that the number of spiral ganglion cells, these are the components of the hearing nerve that we are actually triggering with the cochlear implant. We know that the number of surviving spiral ganglion cells has a direct relationship with how well people do with a cochlear implant. So that is another piece of evidence that shows that. What we then know is, of course, that a cochlear implant must work with what neural health is still available.
One patient may have neural survival pattern like this, another patient might have a different neural survival pattern. Today, cochlear implants are completely blind to that. We have 22 electrodes, others may have 16 or 12. You switch them on, as long as the electrode works, you send information through it and just hope for the best. Great that the brain is able to work it out, and cochlear implants work, but it is not very sophisticated what we do today from this perspective. This is not just theory. Like I said, there is already this relationship with how many of these spiral ganglion cells do you have and how well you do. This is a great study from WashU in the U.S. that looked at two dimensions here. How good is your cochlea, and how close is your electrode?
The worst place to be is if you have poor cochlear health and a poorly placed electrode. Then you are going to be in that bottom left, and this case, let us say you have 8% word understanding. If you come from a hearing aid, that is probably what you had with your hearing aid before. If you look at people that have a better placed electrode, you see that goes up, and these are kind of representative numbers. This is not kind of group average. It illustrates what we are trying to explain there. Then you will do better, but still you will not be a great performer. If you have good neural health, even with a relatively poorly placed electrode, you get a decent result. But where you really want to be, if you have good neural health and a well-placed electrode.
Of course, not everyone is going to have good neural health, but what we really would like to do is at least make understand how that neural health is. That is really where the opportunity with Nexa comes in. How can we use the smartness that we have in Nexa to understand the individual's neural health fingerprint? That is what we have been working on for the last few years, and we continue to work on, not today in research, but of course, we want then to bring that into clinical practice. How do we do that? Like I mentioned before, Nexa has this unique capability to stimulate the nerve, no longer with a floodlight, that is basically, if you want a metaphor for monopolar stimulation, but something that is more like a spotlight or a laser light.
Because with that capability, that requires the sophisticated electronics that we have in the Nexa device, combined with a well-placed perimodiolar electrode, what we can do is we actually scan across that neural survival. So we can shine that spotlight across the 22 channels. At the same time, we need to know how far the electrodes are located so that if we get a poor response, it is not because the electrode is far away. So we need these two factors. But with those two elements, we can now create the unique neural health pattern for every patient. We call that focused NRT. That provides a level of personalized insight in each individual's hearing that we never had before. When we use this insight, we can already now predict the outcomes of an individual four times better than we were able to do before.
What this means is, in the past, we could look at outcome prediction. We could get about 12% outcome prediction based on the old-fashioned, if you want, floodlight type of neural response telemetry. When you use this focused stimulation and we know well where the electrode sits, we can now predict 50% of that. Why is this relevant? One application, of course, is after surgery, you can already get a better understanding in the future which patients will need more aftercare, more rehabilitation, versus those that will need less. Of course, what we really then want to do with this information is then personalize the stimulation itself and the creation of the different channels for recipients. Because that's then how we're able to get to is then how do we customize the stimulation for these functional neural zones.
We've now started to apply these insights, and again, this is data from an early pilot study that we've done. We have now used this focused stimulation capability not only from a diagnostic method. We've now also started applying it in how we generate the sound on a day-to-day basis. What we found with that pilot data is that 1/3 of patients get 2 dB better hearing in noise. Now, 2 dB may not tell you a lot, but it basically means, in many situations, means whether you can participate in a situation or not, because that translates to 20%-30% difference in speech understanding. If you're in a busy place, it might mean I can hear, I can follow the conversations versus not. You can also see it doesn't apply to everyone.
But that's where then the new health prediction comes in, because we now have also the insight to know who this will work for and who it won't work for. Here you can see how the diagnostic insight of that unique neural fingerprint is coming together with the way that we can treat the hearing loss. The other way we've been looking at this is if we have much more precise stimulation, which is again the combination of 22 channels, perimodiolar electrode focused stimulation, is that also improving the sound quality?
What we see is that indeed, when we use this type of stimulation and we ask people to listen to music, and this is, by the way, a crossover study where they try monopolar, focused, go back, go back, so it's a very thorough experiment, we do see that two out of three patients do prefer this type of stimulation when they're listening to music. We also see a greater level of so-called loudness summation, which is a measure to say that we have been able to get more independence between our 22 channels. It's really very nicely coming along, and we're very excited about the potential that we have here. This research does take time. We want to do a thorough job. We want to make sure that we have the right evidence, also the right fitting guidelines, fitting technology, automated fitting that goes with it.
We want to take a step-by-step approach, but I hope that I will be able to share with you what our philosophy is in how we are making real dents into getting that better hearing outcomes, not only in hearing in quiet, but also things like listening effort, music appreciation, et cetera. The other element, of course, if I go back here, back to the start of this graph, is about how do we protect what is there? A lot of this electro-neural interface, of course, story is not worth a lot if we create a lot of damage to that very delicate organ with our electrodes. A lot comes back to how do we protect this amazingly sophisticated but also delicate structure in the cochlea? What you see here in the middle are our first-generation perimodiolar electrodes. You can see they were very large.
What we have done over the last 10 years, we really shrunk them with more than 60%. Today, our perimodiolar electrodes are very slim and atraumatic, and in fact have the same level of hearing preservation as lateral wall electrodes from a mechanical perspective. Of course, there is more that we would like to do in terms of hearing preservation. More than 20 years ago, we started to look how can we potentially integrate also drugs into the device that would help with that hearing preservation. We had the first human pilot study in 2014, where we took the larger version of that electrode, the Contour Advance, and added dexamethasone into the silicone of that electrode. That dexamethasone elutes from the electrode array for about one to three months, over a one-to-three-month period.
What it is doing over that time, it is helping the cochlea, it is helping the body to deal, or the cochlea to deal with the foreign body reaction. As soon as you put something in the human body, the body is going to attack it. What the dexamethasone is doing is helping the body to accept, if you want, and quieten down. How do we know whether that is working? The way that we look at that, we look at the electrode impedances, because the way that we see that is that if the body starts attacking the electrode, there is material that will form around the electrode, macrophages, fibrotic tissue, and so on. That elevates the electrode impedance. What you can see here in the black dots are the conventional electrodes, the impedances. The yellow ones are those that were implanted with this drug-eluting version.
You can see significant reduction of the electrode impedances. Then, inspired by that good result, we applied this to our modern electrodes, to our perimodiolar electrodes, and you can see the same pattern. You could say that is impedances, how clinically valuable is? Does it really make a difference for hearing preservation? The good news is, yes, it does. What you see on the right-hand side, you see over 12-month periods, the black line shows the average level of additional hearing loss that you get because of the fact you receive a cochlear implant. Typically, you lose 20 dB to 25 dB of hearing because of the electrode insertion. With the drug-eluting version, we can halve that. Now it is around 12 dB, so significant improvement of that residual hearing.
And I would say many physicians would say anything that's less than 10 or 15 dB is actually clinically irrelevant. We're getting really close to a situation where we can take that loss of residual hearing pretty much off the table. We're not entirely there yet. There's still more we can do, but I hope you can see how this drug-eluting electrode, which is from a technology, from a manufacturing, from a quality perspective, a very challenging development, but how it is paying off. Now, to illustrate that a bit further, what is actually happening in the cochlea? We cannot obviously look in a human cochlea, but we have invested in a large animal model, and it's called the mini pig, that was implanted with this drug-eluting electrode. The left-hand side, you see mini pigs implanted with a regular electrode. The blue material is the fibrotic tissue.
On the right-hand side, you see the mini pig was implanted with a drug-eluting electrode. In another version, you can see the huge impact that the dexamethasone has in reducing that fibrotic tissue. I hope that I've been able to give you a very good idea of what we're doing in the area of hearing outcomes through Nexa, through drug-eluting electrodes. But you can also see that these are not easy things to follow. They take continuous and prolonged investment, learning from every step along the way, and then refine and refine until we're ready to put that into a regular pathway. I'd like, of course, to talk about how do we also then make everyday life easier for people with a cochlear implant? We've moved a lot over the last 40 years. We went from body-worn processors to behind the ears, to off the ears.
With Nexa, we've been able to shrink the sound processor, and we'll be able to shrink that further into the future. But of course, even better if we could have a solution where people can hear without anything external, and we used the invisible man as the metaphor here. As Dig already has alluded to, I think the rationale for TIKI is very well understood. Of course, it's different for different categories. A candidate may first of all think about the cosmetic aspect and the stigma aspect. Those that actually have a cochlear implant are much less worried about that element. For them, it's more, "How can I live my life in the most convenient way?
How do I do the things that I love to do without always have to think about that external device on my head all the time?" To develop a totally implantable cochlear implant is not straightforward, because the body now becomes an explicit part of the environment. The microphone's in the body. There's a lot of things going on in the body when you eat, when you swallow, when you breathe, as I'll illustrate later. That's a significant challenge, but also the battery is a significant challenge. You all have smartphones. What happens when you charge your smartphone? It gets warm. A TIKI is next to the brain, so we want to have to be very careful, from a patient safety perspective and also from a regulatory perspective, how you actually manage that whole charging cycle.
Big, big engineering challenge to do that in a way that delivers the outcome for the patient, but also meets the safety requirements. Last but not least, you also need to move the processing into the implant, and you want there the same flexibility, the same upgradability as you have with smart implants. All these things have to come together into a totally implantable device. We started this journey in 2005 with three patients. That implant was not upgradable. That implant did have the first-generation microphone technology, did not have any body noise cancellation, but we did learn a few things from that. First of all is we do need body noise cancellation, we do need flexibility, but we also learned that even with a rudimentary product as that, the patients really appreciate the fact that they can hear in any situation.
In fact, the three patients implanted still have the device today. Most of them got a regular CI on the other side. They still use their TIKI device after 20 years every day, typically only for a third of the day, but it taught us how valuable this is. Now, I have here a recording of that microphone at that first generation, where an engineer is talking to the patient. You'll hear the engineer, you'll hear the patient, you'll hear mostly what's going on in his body. If you play the sound.
[Presentation]
Yeah. I hope you can hear that someone is talking to someone, but that other someone, as they're breathing, it's overwhelming the sound that's coming in. Let's play it one more time so this gives you a good baseline.
[Presentation]
We realized we need to do something about this, right? For some patients, it still may be okay. Maybe people get used to it, but when we think about products, we think about mainstream products, because of course, if it's like this, you're also going to spend a lot of time in the clinic with people saying, "I t's good, but it's not so great," and you're going to have to do all this tweaking. Plus, we did not have any flexibility in the implant to have better sound processing. It was all hardwired, like conventional cochlear implants used to be. We knew we needed to do better, so we went to the second generation, where we implemented a noise-canceling technology that is effective in body noise management. Then patients were implanted with that.
We did actually have some device issues with that, so it was a good reminder for us, those around the microphone, that reliability remains important. We will play now the sound. Now, this is a bit different scenario. This is the patient on the operating table, and the surgeon saying, "Welcome to TICI Generation 2." But of course, the patient is here asleep, so let us play that second sound.
[Presentation]
Yeah. You can already hear a big step forward, yeah, in it. Now, it is not fully representative maybe, because the patient is there breathing, but it is in an OR environment. But you can already see how the technology came forth leaps and bounds. We go to the next generation, to the third generation, that is now in our clinical studies. We made further improvements in body noise management, but also importantly, we reduced the size of the device, because we want to minimize the additional surgical time that is required for a totally implantable device.
We also made sure that it is now the latest generation of the NEXOS platform is embedded in this device. So I will play two sound fragments here. The first is an audiologist talking to the patient without the body noise cancellation. You will hear it is already better than the very first generation, but you can still hear the breathing. I will play a second one where we have switched on that body noise cancellation.
[Presentation]
The breathing is there. It's no longer that overwhelming, but clearly you would like to reduce that. Now we've switched on the body noise cancellation. I'll play the next one.
[Presentation]
There's still a bit of breathing, but it's now really pushed to the background. I'll play the original once more.
[Presentation]
Yeah. This is if you don't have any measures for body noise. Again, for some patients, it may be okay. This was just one sample, but we also know that it's quite variable from patient to patient as well. It does show how over the years we've been able to improve the technology. By now, we have taken this generation of the device after initial feasibility study in Australia with 12 patients, now to 92 patients across two pivotal studies. In these two pivotal studies, we have now more than, or across these years, more than 20 years of accumulated patient experience. Across all these studies, we have more than 110 patients. Recently, we did the press announcement, we have 1 million hours of experience now with invisible hearing.
Because we think it's really important that by the time this technology gets to the market, that it's ready, yeah, for prime time, that the surgical time and surgical complexity is as close as possible to regular cochlear implants, that the way these devices are being fitted and cared for is very similar. For the last two sections, I would like to give you a glimpse on what we're doing in Connected Care and also the portfolio expansion. I think I already set up very well for the idea of Connected Care. What I want to do in this section is let's talk about each of the components that we have with Connected Care, but show how we've, over the years, developed a very integrated solution that is designed to really transform that aftercare. Yeah. It starts, but it's all around this connected patient.
In fact, the number of patients actually connected even before surgery, and we expect we can continue to do that more and more in the future. As soon as they start thinking about a cochlear implant, they can already start downloading Cochlear's app. From the surgery to what happens in the clinic, to what we can do remotely with the clinician, to what they can do themselves, that there's a perfectly seamlessly integrated pathway here that streamlines that aftercare, reduces time from audiology so that that does not become a bottleneck, but also at the same time delivers better patient experience and better outcomes. It starts with our surgical care suite that we have. A few years ago, we developed a tool called SmartNav, extremely well received by professionals. It's not only a great tool, it is connected.
The surgeon logs in, they do their measurements, impedances, angular insertion depth, placement check, and things like that. In the future, the neural health measurement. In the future, modiolus proximity measurement that helps to optimize the placement of the electrode. Given that it is a flexible platform on an iPad, we can continue to evolve the functionality to get the optimal information. Importantly, at the end of the session, all that data is not only stored on the device, the clinics also can elect to have that data going to the cloud. I am going to make a small bridge here to Nexa, because as I explained before, Nexa has the ability to store information in the implant.
What some clinics are experimenting with is that during surgery, they do not only run the SmartNav diagnostic, they actually already create the first patient map, what they call an activation map, that they write to the implant. As the patient goes home, they already have their first map in their head. They have a processor with them, and after a week or two, the clinic sets up a remote session, and there is a carer with them. They put the processor on, and you are on air without an additional clinic visit. This is another way how we can use intelligence that we have in Nexa to streamline that care pathway. This is still experimental at the moment, but you can see that would make a lot of sense to bring that into functionality of SmartNav into the future.
Like I said, we have the SmartNav system captures the data, and it then gets transferred seamlessly and securely into the cloud. From there, the clinician who is doing the fitting can grab that data and use this data already to create the first activation map. We have a, today, piece of software that is called Custom Sound Pro. We are working hard to also evolve that to a future generation with even more integration with the other tools. It is already, many of our clinicians tell us that they really like the flexibility that we have, the fact that it is very patient-focused. Of course, we know that the pressure on the healthcare system also means that it is great if we can deliver a lot of that care remotely. A number of years ago, we developed a tool called Remote Check.
You see here the video playing in the background. This is something that the clinician can set up. They say, "Look, we have had your, say, three-month appointment. For your 12-month appointment, let us try to do that remotely. I am going to set up an appointment in 12 months from now. You get a reminder. Your phone will you connect your phone, or your phone is connected with your device. You go through a few steps. It checks the implant. It does an audiogram. It does a speech and noise test." "You can provide, answer a few questionnaire questions." All of that then automatically goes back into the cloud. The clinician has a dashboard. They see, "Okay, yesterday, so-and-so did their remote check." They review the results, and then they can communicate back to the patient, "Look, everything is okay.
In fact, you do not have to come in for your one-year visit or your two-year visit. If they feel something is needed, then we have an extension of Remote Check, which is called Remote Assist. They can set up a video link, where they can connect from their PC with the recipient through chat and through video, and they can make a number of changes remotely to the recipient's system to further optimize their hearing. These are the ways that we built our system, and we continue to evolve that system, of course, to minimize the need for in-person care over the years. The final piece of our Connected Care solution has then to do with the self-care.
We have the app, where there's a whole range of functionalities where patients can, for themselves, control the device, can track their progress, et cetera. The key part of this, part of the presentation, is the connectedness, if you want, of all these solutions, because through that connection, we also get an enormous amount of data about the individual. If you then link that with the neural data that we're going to collect in the future, more speech outcome data that we'll be able to connect through the app. You can see how we can start connecting the dots, and based on that big data, also evolve our algorithms, how we can optimize the outcomes for every patient even more. The last part of the presentation, I'd like to briefly touch on what Dig mentioned as a portfolio expansion.
Portfolio expansion in itself is not new for Cochlear. Cochlear started in the 1980s as a cochlear implant company. In 2005, we added bone conduction. In 2019, we added Osia to the portfolio. You can see TIKI as an expansion of our portfolio. We do see, we also acknowledge, we become aware, in fact, often because people come to us and say, "Cochlear, you have this fantastic technology platform. Couldn't we use that also for other applications?" Because if you look what we have, we have a minimally invasive head-based system, so no tunneling needed to any things in the chest. We have an upgradable implant with fantastic, not only stimulation, but also measurement capabilities, as I've indicated before. We have a world-class manufacturing network. There's a lot of things that if you think about neurostimulation, neuromodulation, we have everything, already ready to go.
Not only that, we also have our brands, we have our track record, we have our academic network, we have the scientific DNA that we have in the company. These things, we're now looking at how can we create new opportunities for Cochlear in the medium and long term. Brian will go a bit deeper in that, in how we're starting to apply some of these assets that we have in ways that create further expansions of Cochlear's portfolio in the future. That brings me to the end of the presentation. I hope that the things that I hope you can take home is how Nexa is going to drive better outcomes. It's a journey, but Nexa is the platform, and I hope I've given you a lot of examples now of what we're doing.
These are still very much in the world of research, but we work as hard as we can to bring them in more hands of more researchers and then into clinical use. How drug-eluting electrodes, what the massive impact is in reducing fibrosis in the cochlea, in improving that residual hearing, which you know is going to be another reason people say not yet for a cochlear implant. How, of course, the advent of TIKI will make hearing aids look like very stigmatizing compared to a TIKI, because TIKI will continue to evolve, of course, and become better and better and even more invisible in the future. Then how we use Connected Care to streamline that aftercare. With that, I'd like to thank you for your attention, and I'm handing over to Brian.
Thank you, Jan. Good morning, everyone. Building from what Jan was just discussing, I get the opportunity to spend a few minutes talking about the medicalization of hearing loss. This is part of a larger standard of care initiative as well that's been ongoing in the company for several years. This work stream has one of the opportunities to be one of the more transformative things that we do within the medical space. As Dig alluded to, I run a cochlear implant center. I'm a surgeon in Baltimore, Maryland. How clinicians, not just ENT clinicians, but clinicians throughout medicine, think about hearing loss, talk to their patients about hearing loss, and then potentially refer those patients for proper treatment is what this is all about.
Part of the work has been trying to define what do we really mean by medicalization, because it's really important. If you look here, it's how we define it as a clinically consequential medical condition that requires the proper diagnosis, the proper treatment, the proper referral for these patients in evidence-based care pathways, and then having the health system able to accommodate that through market access and reimbursement structure as well. There are different lanes of responsibility when we talk about what does it really mean to medicalize hearing loss. The reason it matters is we know this affects communication and language ability for our patients, right? We know there's an enormous quality of life component as well.
What we'll talk about for the next few minutes are the multitude of other health conditions which have moved now from purely associative to looking like they're linked with hearing loss. A lot of research still needs to be done on this as well, because causation is often different than association. But I'll walk you through some of the literature that has just come out in the past several years, which has really started to change how clinicians talk to their patients about hearing loss, and part of this is how do we accelerate that process as well. This has broader implications than purely just about the hearing loss, but about their overall health condition, and it's been shown to be cost-effective for the patient and for the health system as well. The clinical responsibility is clear when you talk about medicalization, right?
We have medicalization for a multitude of other health conditions. We will talk about a couple of those in just a few slides. This is not something new that we are taking on here for hearing loss. We have to define the referral and treatment pathways. It has to be based on the stage and severity of the disease, and then we have to provide the proper rehabilitation, which in many cases is a hearing aid for that patient. At a certain point, the data is clear of when that patient will benefit from a cochlear implant versus a hearing aid, and there is even stronger data that is on the horizon coming soon that we will talk about in a minute. You have to continuously iterate on this.
There is a deluge of data that is coming in just in the next few years, along with what we have seen just in the last 24 months. These recommendations will need to change in real time, and we have to set up the pathways and the platforms that will allow that to happen. The health system has to be able to accommodate this change in the pathway. The increased inflow of patients that come through, how to work them through the system. You heard about some of the bottlenecks that we are working through with our clinicians to change the care pathways. Technology plays a role in that as well.
We have to enable those patients to be able to access this in an equitable manner so it is not discriminatory as who gets access to this technology, because again, it is a cost-effective solution that has been found for the health system as well, with significant downstream savings and ROI that we will talk about in just a minute. The important thing is we know how to do this. We have already done it in pediatrics, right? Dig alluded to the timeframe, and we do not have to wait until the end, and you can see that here, where it is continued accelerated growth that we saw in the pediatric segment as we work through creating standard of care in this space. It started back in the early 1990s to mid-1990s with universal healthcare, universal screening for newborns.
As the universal screening became more popular, we started to see a growth in the identification and the referral of these babies for their implantation. That then changed in about 2000 when we had the FDA indication moving it down to 12 months, so now we are nine months. The cost-effectiveness was proven with hundreds of thousands of dollars in savings per baby implanted, with not having to do specialized education costs, normalizing speech and language development, along with a whole other multitude of things of keeping them in the workforce longer, higher earning potential, less chance of unemployment, all of those things proven for children implanted with a CI. We were able to expand a public reimbursement for cochlear implantation for millions of patients who were living in a public system who previously had not had access to that technology, and then the change for bilateral implantation for babies.
If you look back in 2010, we were at about 50%. We are over 70% now in 2026. So, that is a long time horizon, but with significant growth along the way, and that is where we are now in the adult piece as well, in the middle of that journey. Dig put up this slide earlier. I just want to spend a few minutes going into a little more detail, because it shows we are not needing to work on this in serial. We have many different work streams that are happening in parallel, and many of them actually support each other in a foundational element. These are the pieces that we need to form that foundation for the medicalization of hearing loss that will propel us forward over the next few years.
There are four main work streams on this where we talk about the evidence, guidelines, policy, and how to actually change clinician behavior. When we talk about the evidence, that started back with the Cochlear Chair for Hearing across the street with Macquarie. Dr. Bamini Gopinath is the chair there now, starting back in 2017 of a joint arrangement to accelerate this process of understanding the importance of hearing loss and treating it appropriately. The year after that was the Cochlear Center for Hearing and Public Health at Johns Hopkins that was established with Dr. Frank Lin, who was the head of that until just last year when he moved across to Apple, who was instrumental in some of the things that we will talk about here today in that partnership.
The Hearing Health Collaborative, which is both U.S. and in Australia and New Zealand, bringing together pools of surgeons and audiologists who are the experts in their field to be able to help create the next generation of guidelines to guide the medicalization journey that we are all on as we speak. The COACH study there, that is based out of Nottingham. That is the first RCT trial directly comparing cochlear implantation versus hearing aid. That has always been the holy grail in our field. That is the study everyone wanted to do, but it was unethical to be able to do that in a normal setting, to withhold cochlear implantation when we knew it was beneficial for that patient.
The reason that study was able to be launched was the NHS has very strict criteria, and it was 80 dB or worse hearing loss, and we were able to target 70 dB to 80 dB for that population. Patients who were not eligible today within the NHS to be accessing this technology were enrolled in the study. You will see at the end there, this was 130 patients where it was powered for, started in 2021. We are up to 118 patients randomized now. So we are getting closer to the end of that study and all anxiously awaiting the readout. The landmark ACHIEVE publication, that was out of the Cochlear Center and Dr. Frank Lin, talking about the 48% reduction that we saw in cognitive decline in only three years in an at-risk population.
That was really transformative in our field, along with the Lancet Commission study that we will see in just a second. The Cortex project done internally as we started to get this multitude of new data that was coming in from the literature over the past few years, how do we pull this all together to be able to then turn this into an accessible dataset that our clinicians in the field can access that changes how we talk about hearing loss as well? For the guidelines, the first one was Dr. Buchman. You saw one of those slides earlier from some of his basic science research, pulled together a large group of clinicians to create the first-ever consensus statement on where we are for adult cochlear implantation in 2020. That was the foundational piece that then directly led to the Living Guidelines.
The Living Guidelines, another group of worldwide experts brought together to say, based on available literature, what are the treatment guidelines that we would recommend through the entire care pathway? The reason they are living is because these new pieces of evidence are continuously coming out on a yearly basis. They need to be updated in real time as well. We are on version 3.0 of that now. Adoption, over 25 countries have now adopted those Living Guidelines and working through their own state and national societies to get that endorsement as well, because you need to translate this into their local and regional environments.
Then changing that aftercare program that you heard about there from Dig and from Jan to remove that bottleneck, being able to create that platform, create the evidence for the benefit of removing some of those appointments, actually better patient satisfaction without ever sacrificing outcomes for the patient as well, and opening up the clinic capacity to help that 95% of patients who are not accessing the technology today. Part of the important work stream is always the advocacy of the patient advocacy groups coming together. CIICA was the Cochlear Implant International Community of Action. That was the first time that they pulled this worldwide together for all the community groups together, now representing over 70 countries from a single voice from a community action standpoint as well. We have had two very important World Health Organization statements.
One, the importance of public health systems funding hearing testing and hearing treatment, and the other now for the first time, linking it to healthy aging and cognitive decline as well. Really important landmark pieces. Then advocacy and partnerships with the International Federation on Ageing and IFOS, which is the world's largest association of otolaryngologists, and is now headed by one of our busiest cochlear implant surgeons, Professor Ramos, in Europe as well, with tight collaboration during this process. Then finally, we need to then create the behavior change, right? The way you do that is you need to simplify this process.
You need to make it easy for the referrer, whether it is an audiologist, a GP, a geriatrician, to be able to understand what does the literature say, what do the tests say, and how do I easily read that and then act upon that in the best interest of the patient to send them on? Part of that is a vital sign for hearing. Everybody in here could probably quickly rattle off what your last cholesterol was, what your blood pressure was, what your blood sugar was. Nobody in here has any idea what their hearing is, right? There is no number that is associated with it. Even your vision, you could probably say you were 20/80. So how do we create that vital sign?
Dr. Frank Lin was instrumental in helping to get that off the ground as well, and now along with the Hearing Health Collaborative, so that everybody has a vital sign they can talk about related to their hearing, just like you would for other health conditions, because you need that biomarker along the way. 60/60 was a simplified way of reading an audiogram to simplify for the audiologist sitting in an office talking to a patient about whether a hearing aid or cochlear implant is better, and simplifying if your PTA was worse than 60 and your word discrim was less than 60, very good chance you are going to benefit from cochlear implantation. Go talk to an expert at that time. You heard about the DTC and DTP from Dig. We are going to hear more about that in just a few minutes.
Part of a larger global referral program as well, along with a referral support tool that gives the referring audiologists the confidence to know that, yep, my patient is very likely to benefit from a cochlear implantation. I should send them on for more education at that time. Then a big cognition campaign that we are doing some targeted work on right now in some of our largest markets. Then Adult Hearing is a non-branded site of educational resources for the referring audiologists, along with that referral support tool and some of that hearing testing as well. The way that you drive more referrals, right, is we have to be able to create now with that foundation that we just described there on the last slide, you have to now define it as a medical disease, right?
We have to take that literature, put it together, and it is a chronic disease that needs the diagnostic staging criteria and referral. Those numbers and the severity then has to be the basis for further action, which defines the further action of that referring physician with better integrated and simpler clinical care pathways that are not hard to navigate either for the patient or for the referring provider, and that you have to then provide the public health adoption and payer adoption to allow the payment system and a value-based care system to understand the benefit of that treatment to both the patient and to society. We have done all the things in the top box there that we talked about, and then in that bottom box, getting those clinical guidelines in place.
We talked about 25 countries already adopting it, but getting them endorsed by local societies and getting teeth behind them as well. Using for the first time claims data modeled to hearing severity data to show the health economic benefit that we can do now of the hearing intervention. Normalizing screening criteria. Several countries around the world already have programs in that now in place. Then, that bottom one for ICD staging, we are going to talk about here on this next slide. Part of every disease is you have got to get a staging system for the severity of the disease, which then defines your further treatment. We have that for a multitude of other health conditions. An easy one is kidney disease, right? Kidney disease goes zero through five. If you are one, two, and three, it is medication and lifestyle change.
At four, it is much more aggressive intervention, and you should be considering and getting prepared for the interventions required at stage five, which is dialysis or kidney transplantation. Every clinician in the world works through the same steps. Something similar to that is what is being worked on right now through a joint collaboration, which you can see on the right, between Macquarie, Mayo, in the U.S., and Cochlear, to advance that staging system based on available literature today in a modified Delphi process as well of what will be a clinically applicable and accurate staging system, which then defines treatment. Once you have that staging system, that then needs to get worked into creating the specific codes, the ICD-11 codes, in conjunction with the World Health Organization.
That work has already started as well, because then you can track the severity of the disease, track the referrals, track the treatment, and track the outcomes for these folks, which then has payment implications as well to make sure we have market access for these patients that are coming through. All this work is ongoing as we speak, and will only accelerate this process. What I mentioned earlier is we know the benefits from a hearing standpoint of treating with a cochlear implant versus a hearing aid in that moderate to severe to profound hearing segment, but the conversation is now changing and broadening beyond simply improving an audiogram. It now has been shown to have significant implications in cognition. There is probably 20 different studies that we could have put up for this slide, all published within the last several years.
These are four or five of the biggest ones that have been published here. The Lancet Commission in 2017, 2020, and 2024 did issues looking at what can you do to prevent dementia. All three times, the biggest modifiable risk factor was treat your hearing loss over a multitude of other health conditions. That really changed how the medical community started thinking about hearing loss. Hearing loss intervention associated with improved cognitive functioning.
We could not have said that two years ago. You can see that was 2024, 2023, and 2026, where those studies came out. That we have been able to show for the first time, researchers have been able to show, that if you treat that hearing loss appropriately, you are able to slow down, halt, or in some cases reverse the cognitive impairment on certain different metrics that we were able to follow. Slower decline in CI users.
This comes out of Melbourne with Julia Sarant, looking at hearing aid versus cochlear implant and the ability to slow down or even reverse the cognitive decline on several metrics. That is ongoing and actually expanding. We will talk about that in a second. A large population health-based study out of Korea with hundreds of thousands of folks in the comparator group, looking at the cognitive decline with hearing loss and various kinds of treatment. It is really a telling graph that you can see at the bottom, where normal hearing patients and cochlear implant recipients had the same level of cognitive decline, while those with hearing loss who did not get treatment are the orange line at the bottom. The green line is if you treated them with hearing aids, showing a clear separation of cochlear implant versus hearing aid in preventing cognitive decline in this population.
They have their national database that they were able to use as a comparator. This was really quite impactful. There is a lot of stuff coming just in the next few years. We have across the street, Dr. Gopinath doing the HALOS study, and that study is looking at the social, cognitive, physical outcome, and economic benefits of cochlear implantation and hearing aid treatment for hearing loss patients. Looking at outcomes of CI versus hearing aid for severe hearing loss patients as well, and within their cognitive ability. The impact of their hearing intervention for adults with memory impairment, taking an at-risk group that comes out of Columbia University with Dr. Golub, looking at an at-risk group with mild cognitive impairment already and treating them with either hearing intervention or not, and looking at the benefit in a short period of time.
The long-term effects of cochlear implantation is a continuation of Julia Sarant, and the real-world outcomes compared to cochlear implant and hearing aid recipients at University of Iowa. All of these things will be coming in the next few years, likely further strengthening. The health economic argument is clear as well. This was based on U.K. data, 50 and over, for adults with severe to profound hearing loss. We knew cochlear implants were cost-effective when we only looked at the hearing improvement. But with the addition of falls and with the addition of cognitive decline data, it further strengthened the ROI. 23%-24% fewer falls, 27%-35% fewer cognitive decline, and then from a patient benefit standpoint, fewer deaths, 22%-23% fewer deaths related to falls, and 26%-35% related to cognitive impairment.
The ROI went from 43% to 53% with this new data on falls and cognition. It just further strengthens the importance of proper diagnosis and treatment. Finally, related to falls, all new evidence that is coming showing the importance of properly diagnosing and treating the hearing loss because of the potential link that we are seeing to falls and balance overall. Increased falls risk with degree of hearing loss. A dose-response curve is important for anything that we do in medicine, right? If it has a linkage, the more you have, the worse your condition should get. For every 10 dB increase in hearing loss, a 1.4-fold increase in falls, right? That is a really important linkage that was found in the literature.
The direct cost is over $80 billion per year U.S. related to falls, and that hearing intervention had a 27% reduction in falls. Putting a cochlear implant in people, 72% of the population in that study showed a benefit in their overall balance function. Three large-scale studies that are ongoing as we speak, looking at spatial orientation in CI users in over 700 patients, looking at the benefit of unilateral versus bilateral implantation, because remember, the inner ear is doing hearing and balance. We will talk about that in one second.
Then the objective measures pre and post, looking at if we pick the worst vestibular ear or the better vestibular ear, that is at University of Virginia, can we find this as a diagnostic criteria related to their balance function, which could point us in a better direction for which ear is going to get better performance on a hearing side as well. Then linking that, the vestibular implant potentially for people with normal hearing to restore gait and postural control. So one of the areas of potential future study. You saw this slide from Jan, who alluded to the platform that we have and the strength of the platform and the strength of the research network and the relationships, along with the expertise in regulatory and quality and clinical to get this done.
Many different potentials that are out there in terms of head and neck stimulation, but focusing on just a small number, and one of those is vestibular, right? Because it is linked to the same hearing organ. The cochlea does hearing and does balance. So a bilateral vestibulopathy is the loss of balance function in both of your ears. If you go walking down the street and shake your head side to side and pick a point to look at, you will have no trouble keeping your eyes on that point. The way you do that is your ears are telling your brain how fast are you rotating your head. Your brain tells your eyes to rotate in the opposite direction at the same rate. You obviously do not think about that. If one ear is broken, the other ear can compensate.
If both ears are not working correctly, your brain cannot compensate, and you get what is called oscillopsia, and the world bounces. You cannot read, you cannot drive, you cannot walk. It is completely disabling for these patients, and there is no available treatment that we have for those patients today. Why it made it a very interesting area for some early research, we completed a pilot study with a feasibility study, which is active right now. It is an area of exciting research and looking at what are the regulatory implications, clinical data that is required as part of the further research platforms that we will do to see how we can potentially help this patient population. So I want to end just by showing you this video.
This was a patient in one of the early studies with a significant bilateral vestibulopathy, and you will see it in two conditions, with the implant off and the implant on. We will probably play the video twice, please. Yeah, it is fairly dramatic. Just one more time, please. Yeah. You can see why this is an area of potential future exciting research that we will continue to look at. Thank you for your attention. I will hand over to Dig.
Brian, well done. Okay, thank you. Thanks, Brian. Let us click on. I have actually met two of the people who have the vestibular implant, and it was absolutely life-changing for them. There is always quite some time between seeing a life-changing outcome in the clinic to being able to go further than that, but certainly exciting area. Okay, so we are now going to sort of switch gears. At Cochlear, we always need to be working at two clock speeds. We need to make sure that we are setting up for the long term, delivering on the long-term strategy at the same time that we deliver right now. We have looked in at technology, we have looked at medicalization, both longer-term programs that have delivery on the way.
Now we are going to switch to look into our regions, where we need to deliver each day, and how do we take, how do we launch products, how are we driving referrals now to deliver results in the shorter run. I am presenting on the U.S. today, as most seen in the announcement we put out this morning. Lisa Aubert will be leaving Cochlear later this year, and I do want to acknowledge Lisa's 32 years with Cochlear and the amazing contribution she has made to patients right around the world, to our professional partnerships, and to Cochlear's culture over that time as well. Okay, so in the U.S., huge potential market as we see everywhere. Over 3 million people with severe to profound hearing loss. More than 10,000 people a day turning 65.
That turns into about 50,000 new cochlear implant candidates each year, which is more than twice the rate of adult cochlear and senior cochlear implantation in the U.S. at the moment. This is a big pool. 79% of the surgeries that are done in the U.S. are in the adults and seniors. That demonstrates it is one of the highest in the world, up there with Australia. Demonstrates that the penetration, while still low, is higher in the U.S., higher in Australia than we have seen in the other markets. Okay, but let us go into a little bit further around just what are we doing to drive referrals? First, just more of that data. We have been growing that adult and senior segment in the U.S., so that is why it has gone from 69% to 79%.
That is both for penetration, but actually indications have expanded as well, both in terms of things like single-sided deafness. As the technology and the outcomes get better, the threshold at which people qualify for a cochlear implant lowers. That is where the 60/60 criteria that Brian mentioned came in. So, 60 decibel hearing loss and less than 60% words right with the hearing aid. That is actually a reasonable level of hearing, but the evidence is clear now that those people will do better with a cochlear implant. So that technology advancement actually expands the category as well. Now I want to look at referral and thinking about the barriers chart that you have seen a few times. How does this work in numbers in the U.S.? We have got 1,000, take 1,000 people with severe to profound hearing loss, 800 of them will have hearing aids.
That is actually a good thing, right? Severe to profound hearing loss is absolutely debilitating from the level of hearing loss, and 80% of people know that and they go and act on it. Probably a fair few of the 20 have tried and then pulled out because the hearing aids are not working for them. Then only 100 get referred to a cochlear implant clinic. That is obviously the biggest gap, and that is where referral comes in, and that is what we have got to work to close. But even when the 100 get referred, only 60 get evaluated. So 40 people have dropped out there. Why have they dropped out? Our hypothesis, backed with some of our research, is it is a really soft referral.
We have members who have worked at Cochlear, spoken to people who got the, "You could think about a cochlear implant for you, but I will not tell you anything more about it." That is part of the referrals. Not just thinking how do we get the 800, more of the 800- 100, it is really more of the 800- 60, and lifting the 60. Then we see people, some might not necessarily qualify, but we are at three-quarters who do qualify, and then people still withdraw before surgery. That is where we get to things like the fear of surgery. Is the benefit enough? That is variability of outcome. Do I understand the impact of cognition and the fear of loss of residual hearing? So things that we talked about from a technology perspective and an evidence perspective to increase the percentage there.
We have got to work across this chain, but it is the 800- 100 or the 800- 60 that is a huge opportunity, and that is the importance of medicalization, but it is also the importance of building referrals. One way to look at that journey from the 800 to the surgery is to think about what is it where we are intervening and what is the success rate there, so where people are steered through that path, and then the self-navigated part, what we call self-navigated. So where we are not intervening, where people are at the whim of the medical system or of the ad hoc path that they follow.
What we see over time, and I will talk into these in a little bit more depth on each, is when we look at the part that Cochlear supports, and that is up in the U.S., about a third, there are two ways we do this. One is through our direct-to-consumer, so digital connection and promotion and finding people online who are searching that they are frustrated with their hearing loss or cannot hear well with my hearing aids, but also through professional partnerships, people who will refer directly onto us, and we can then help steer them through the journey. Both of these, we get to intervene, and then we get to be able to provide the evidence that Brian has talked about, be able to explain costs, where costs are an issue or not for people, and the journey and the expectations.
What we saw when we looked at this last year in the U.S. is we still had 10% growth in quite a difficult market with a whole bunch of headwinds. We still had 10% growth in this section in the U.S., which gives us confidence if people get a strong referral, they are more resilient to the economic conditions that are around them. That is where we need to get to. We cannot be, and we do not want to be, a condition that is contingent on broader economic conditions. Medicalization, the evidence of the path to do it, why we believe it works is when people do have that information, they do go through.
Some of the ways that we do that is just some of the ways we advertise in print, yes, American Association of Retired Persons magazine, that has been a big source of leads for us over time, and also online. One of the things we have been able to do now is the healthy aging campaign we have been talking about for a while. As the evidence for cognition gets stronger, we are now able to run cognition-related campaigns. Now, hearing aids have been able to do this forever. Hearing aids are regulated to a very different level than we are, so we need the higher level of evidence to do that. Now we can run cognition campaigns, which we have done now in Australia. We have just done a pilot in the U.S. We see significant uplift in the click-through rate in these campaigns.
People, again, more indication that people think about their hearing loss, and we have probably got an ad to them because they are concerned by their hearing loss. When they see there is a more significant consequence, they are more likely to take action. Early days on the data from online campaigns, but definitely encouraging what we are seeing. We are going to continue to expand what we do from a DTC and professional referral, but we also know that that is never going to take the extra 2/3, or it is also going to cost too much to try to get across the whole lot. The point of medicalization is actually we do not need to lead candidates by the hand through all the way to surgery.
When we look at the self-navigated part, there we see that there are really, for the people who do get through at the moment, there is broadly two paths that they follow. One is that they have come from a retail channel, from a hearing aid, so they have been fortunate enough to be working with a retail hearing aid acoustician or audiologist who will refer on, and also from the medical channel, so from an ENT practice typically that is not doing cochlear implants who do refer on. When we see those referrals that come from the medical channel, we typically see that they move faster through the process. Again, that is a sign they have got better information about where to go, why to take action, and what to expect, so they tend to move faster.
Again, more indicators that if we can build out these referral pathways, people will come through more as a routine and at a lower cost than us helping them all the way through. But clearly, that is our goal, is to lift this, turn this self-navigated section in the U.S. and around the world into a more clear and consistent referral paths. The way we are going about doing that in the U.S., and we have been talking about this for probably the last year or so, is building out a program to actively target potential referrers.
So we have taken 10 cities in the U.S. where there is capacity in the cochlear implant clinics for growth and an interest in driving growth. We have then employed people to go into these areas to actually go round to potential referrers, whether that is the medical ENT channel or to hearing aid retail. We back that up with online marketing and targeting of these professionals, so it is both an online and a face-to-face way of getting to potential referrers.
That is where we then do this clinical education. Having the clinical practice guidelines is a really important part of how we build out the referrals. Just turning up and saying, "Do you know about cochlear implants? I am from the manufacturer," is quite different from turning up with, "Do you know your association has approved clinical practice guidelines for age-related hearing loss?" What we are actually seeing as we are doing this, quite a lot of them actually do not know that yet. Perhaps not surprising because the guidelines are new, but it is an opportunity to educate, and that will take time to educate.
As we can start to get referrals, we have got to sustain those relationships with the latest information, with changes in indications. People seeing, particularly, and this is about closing the loop, seeing the results from people who have got a cochlear implant compared to a hearing aid and seeing how much better they are hearing. So it is early in this program. We have got people in these 10 cities now. We are learning. They are learning what gets them in the door, what are the right messages, what is the frequency of calls, how do we measure performance. That is a cycle of doing. We are starting to see some referrals come through.
But this is a program that is not going to deliver much this year, but certainly over the next few years has potential to really lift the referrals, supported by the medicalization evidence, which will take longer to come through in the bigger volumes where that real potential is. Okay. And with that, we are now going to take a break before I hand over to Stu, and someone needs to remind me how long the break is or when we are meant to come back. 10 minutes. Okay. 5- 11, 10:55. Thank you. And I think we have some tea and coffee things outside.
[Break]
All righty, we will make a start. Thank you for coming back promptly from the break. I hope everyone is reveling in a Friday morning without email. My name is Stu Sayers. I look after the Asia-Pacific and LATAM regions for Cochlear. As Dig said, I have been here about 10 years now. I am going to talk today, Dig mentioned these three themes around expanding access, changing the category with innovation, and then simplifying the care. Within APAC, we are working, and LATAM, we are working across all three of those themes. It is fair to say more of the work for us is in the first two. I am going to zoom in a bit more on those and what we talk about today.
If you think about the key messages to leave with, firstly, it is about using what we call GAMA, government affairs and market access, to try and establish the playing field and try and increase the access and increase the funding for the treatment. We will talk about some examples of that. Then once the playing field is established, how we play on that field. As Dig talked about with the U.S., that is all about that referral funnel, and how do we expand it, and how do we pull people through that faster. China is obviously a huge part of our region. It is a big part of the company overall now. About one in six of the implants we did in 2026 was in China. We will spend a little bit of time talking about the changes that are happening there.
And then lastly, that notion of really transforming the category through innovation and how we are using product launches like Nexa and Osia and the marvelous things that roll off the R&D pipeline to really good effect to do that. If we start with that GAMA, what do we really mean by that? That is working with the payers and the authorities in each country to identify what devices should we launch, and particularly, how do we get reimbursement and how do we get improved reimbursement for those devices?
As those devices come off the conveyor belt, we typically have a choice, a trade-off to make of, we could put it out on the market faster, but almost by definition, if you are going out faster, you are taking the current pricing and the current access standards. Or we could choose to not launch it straight away and try and influence that playing field. In 2026, we had some very, very good payoffs for this activity. I would say this is actually an unrepresentatively high level of payoffs because these things are long-term.
We are typically talking about studies that might take six or 12 months to build the evidence that you want to take to the payer, and then 6- 12 months or more interactions with those payers, with those other players and stakeholders in that environment to discuss with them, to convince them that we have got something here that is delivering a materially better outcome and is worth a higher level of reimbursement, and potentially a new category as well. As you can see here, we managed to achieve that in Korea and Japan. Around Osia, we got some vital increases around Nexa and new category recognition for Nexa. Even in Australia, where treatments are very well established using uplifts in the latest round of Baha processors that have secured a price increase there as well. Even in Australia, the work here is never done.
Even in Australia, which, as Dig showed, it is one of the best-served markets in terms of the penetration. Still far too low, but better than most other markets around the world, and the funding is actually quite good. As you can see here, it is not perfect. Actually, there are some significant gaps even still in Australia. If you are under 26 today in Australia, you are very well served. It is probably the best country to be severe or profoundly deaf because everything is fully funded. If you are above 26 and you are in the public system, you are still funded for one side, but you may be limited by state funding caps on the surgeries. There is some access, but it is not full.
The biggest gap we are chasing in Australia right now is that your right-hand side, if you happen to be implanted over 65 and your device breaks, or it gets lost, or we introduce a new one with a radically better level of hearing, you currently have no access to that if you are in the public system. If you are in the private system, you can. If you got implanted under 65, you can. But not if you got implanted after 65. It is a significant gap for us, and it is the top priority for the GAMA work in Australia, along with trying to address those other gaps as well. If we then shift gears to once we have established that field, how do we play in that field?
This is, you will see some large replica of the work that Dig talked about in the U.S., because a lot of the learnings from the U.S. we are taking into Australia and adding to them. Then as you will see later on, we then take those learnings and export them into other places around the Asia-Pac region. We look at Australia first. As a whole market, it is roughly 50/50 public healthcare, private healthcare. But if you then look at CI surgeries, what you see is it is only about a third of the surgeries happen in public, and 2/3 happen in private. Why is that? It is really down to two things. One, some of those public systems hit their caps. If you are in Queensland, there is a state cap.
Once you hit it, surgery stop for the year, and they start again when funding gets reissued the next year. Some of them is just constraints in the system, and again, back to the GAMA work to try and increase those over time. Also, we know we can drive people through that funnel. We can widen the funnel, and we can drive them through faster. Where we can do that and there is not a cap, like in the private system, we can actually get those surgeries accelerating faster. What we saw in FY 2026 was actually, oh, sorry, 15% growth in the private side of the market where that funnel acceleration was working. We were not able to do that yet in public, so that would have led to a larger backlog being built.
Dig talked about this notion of the two sides of the funnel, the one that we see directly, and the one where the patient is self-navigated. What we do there, the outcome we are aiming for is the same, more patients going through. The way we go about it is slightly different depending on whether you are in the we are helping you side or the self-directed side. I am trying to bring that to life a bit more. If you think about the old journey, so the then journey, and a lot of patients are still in the then journey. First off, it is not linear like this would suggest. These patients, it is not uncommon when they finally get to surgery, if they finally get to surgery, that they have spent 10 years or more in that world of, "I have got hearing loss. I have done something.
I am not happy with what I have got. I have gone to get help, and I sit and I loop in a hearing aid channel, possibly bouncing back and forth between that and an ENT, but may not be getting a hard referral. Maybe I am getting a soft referral, and I never actually get to the treatment I need." We are trying to find those patients, and if in the yellow row there, if we are contacting them, then we are trying to actively find them, seek them, sift them.
Filter for, what is your hearing loss? How unsatisfied are you, and how motivated are you? Because that is a key driver. Then once we identify someone who has got hearing loss and they have got that motivation, then we want to be connecting them. We want to be steering them to places we know they are not just going to get handed off as, "Oh, it is just age-related. There is nothing you can do."
They are going to get a hard referral to, "Okay, you need to go and see this surgeon at this clinic and get assessed for a CI," and then support them through that and through their ultimate hearing journey. If they are on the non-contacting us side, on the self-directed side, just again, we are targeting the same things, but it is more than focusing the activity on training the professionals, both the CI surgeons on how to build referral networks to have more flow coming to them, and training the referrers, back to Dig's point around how do you identify more easily who those right patients are, then making sure those referrers are more of a hard referral, not a soft one.
That was what was driving the private growth in Australia in 2026, again, learnings from the U.S. and Australia that we can then export to other markets. Again, if we think about how mature our markets are, a good quantification of that, I would say the math is really rough on this, but it is roughly right. Implants per million of population, Australia, about 80, U.S. about 50. That is a combination of pediatric penetration is much higher in Australia, and the adult penetration, the seniors penetration is better, but still nowhere near good enough. We are still at best 10%. If we then look at our other big developed markets in my region, South Korea, Japan, much lower rates, much lower levels of hearing health market maturity.
That means there is a big opportunity, it also means that learnings we get from the more mature markets, we can distill and then import them into those markets. That is learnings around things like the GAMA work. You are talking to different payers, but the information you are using is quite similar. The packages you are putting together to convince those people, it is the same information. The actual content itself, so the campaigns we use, the way we talk about it, as Brian Kaplan said, messages around cognition, we know they are starting to resonate more. We can replicate that, oftentimes it is changing the imagery and the language, but not the core theme. Clearly around the products, the products are the same. This funnel work, again, we are seeing increasingly the relevance of that in those markets as well.
If we then look at Korea as a start, then we will talk about Japan. Korea, less mature than Australia, so about 30 per million. Very well-serviced healthcare market, one of the highest rates of beds per population in the world. Very high skilled physicians, really impressive hospital setup. Actually, the CI market there has been growing. It has been growing at about 9% for the last four or five years. We have been growing at about 11%. What we see in Korea, still this huge untapped opportunity, right? We would love to be 80 per million or higher in Korea, much higher above that. It is very concentrated. So 70% of the volume in Korea happens in five hospitals. There are two things we are trying to do there in a material way.
One is drive more flow to those hospitals, because there is still, there is a lot of patients who are not getting there who could, and increase that 5- 10 and 15 that are doing material volume. As a result, what we are getting the team to do there is broaden their focus from looking after the top five centers really well, and they still do, but also broadening their focus to be, how do we pull more volume in to those centers, and how do we expand the number of centers that are doing it and building those referral networks around the next five and the next five hospitals? Again, the numbers on the right, you can see we are starting to get some traction there, both in terms of the numbers of centers doing surgeries and the rate that they are going through.
Japan, earlier again in terms of its maturity. Actually, there is a number of factors that really highlight Japan as a less well-served market for overall hearing health, and particularly cochlear implants. Roughly the same number of people try and get help in Japan, the same proportion try and get help who have got hearing loss, but the number that then get a hearing aid, much lower than most other developed markets. Satisfaction with it, much, much lower. The number who then ever hear about CI and the awareness to CI, much lower again. The job is harder in Japan, and that is part of the reason why the penetration is so low there.
The work in Japan needs to be more narrowly focused on a very small number of centers, because the reality is, in Japan, if you get referred to any professional, the chance that they know about CI and are confident enough to have that conversation is very low. We want to go first where there is capability and motivation, and then look to expand that over time. It is a huge opportunity, but underserved today. Again, what we have seen is where we can focus that attention, where we can focus that awareness building and the referral network building, we are seeing good growth to be possible, but it is on a very, very small number of centers today.
If we now change from the very much mature or starting to mature or mature developed markets to China, which is now an interesting hybrid of emerging and developed at the same time. FY 2026 was a huge year of change in China. We saw a couple of trends there really starting to move dramatically in that time. You would have heard about the government introducing volume-based procurement across a number of sectors in healthcare. What is less understood is while they have been doing that, they have also been introducing a thing called BMI, Basic Medical Insurance. If you think about it is kind of like Medicare or a broad-scale private insurance, but publicly funded.
Pre-VBP in about FY 2022, the number of people who were covered for healthcare and covered for CI, and with a high degree of reimbursement, it's maybe at best a third, maybe 35% of people in China had that coverage. Post-VBP and today, that number's 85%. 85% of 1.5 billion people have funded access to CI. There is a small amount of copay needed, but it's less than the cost of one set of hearing aids. The access has exploded in China, and we saw a huge volume growth off the back of it. The other big shift we're seeing there is in the age of the patients. I remember when I started back in 2016, it was almost 100% pediatric market and relatively small. Fast-forward to FY 2026, it's now a majority adult market. The peds volume is still high.
Birth rate's declining, obviously, but much larger portion of adults getting CIs in China, and we believe that that's heavily influenced by people who've had hearing loss and are now getting it treated because they've got access, and that desire to stay in the workforce. It does link back to some of the stuff that Brian talked about with partly the cognition linkage, but also you're twice as likely to be unemployed globally if you have severe to profound hearing loss as well. Some big swings in China, and it's obviously a big part of our region and important for the overall company. Lastly, just want to touch on that notion of shaping the category through innovation. Again, 2026, we were lucky to be the beneficiaries of some stellar work from Jan and his team, and obviously Greg actually manufacturing it.
That's some of the noises you can hear upstairs. Everywhere we launched Nexa, everywhere we launched Osia across the region, winning share and growing either the whole market, if it's somewhere like Australia where you launch Nexa and that becomes the product across the whole market, or if you're going to emerging markets like India, Thailand, Vietnam, Indonesia, Malaysia, you're typically looking at a tiered market where we'd be launching Nexa into the top tier.
You're either trying to grow your overall share or you're trying to grow that top tier, higher priced portion of the market, and some really great results across the board everywhere we were able to do that. That's all I wanted to cover today. As I said, it's established the playing field with GAMA, use the funnel to then pull people through and pull them through faster, and then keep bringing the innovation to stay ahead and to keep shaping and driving the category. With that, I'm going to hand you over to AB to talk about EMEA. Cheers, mate.
Cheers. I think, hi everyone. My name's Anthony Bishop. Everyone calls me AB, which, if you know anything about the cochlear implant world, that's awkward. Please think of me as ABC, Anthony Bishop from Cochlear. I like to think that's been my nickname since Allan Border was a great cricketer, so I keep that nickname. I am going to talk to you about the future, but I want to acknowledge that last year was tough in the EMEA region. You have the commitment, and my team, we are focusing on getting that short-term right, and we are, while we talk about the long-term. That's where we are going to spend our time today. Let's think about EMEA. I think it's really important we give you a picture of EMEA. It is a large market, and I am going to show you how many countries in a moment.
There is a very, very, very attractive hearing aid market. Strong growth, and there are lots of patients, over 15 million patients with severe to profound hearing loss. We are seeing lots of system forces, and Dig spoke about some of these, and you have seen them. We certainly know in EMEA that things are changing. Governments are thinking a lot about healthcare, and you will see why this is so relevant as we go through. Aging population, there are changes in AI and automation. There is a lot of conversation on funding. In the developed world, it's predominantly a government-funded system. There is a lot more change in the consumerization of healthcare. The most important thing for us is understanding the drivers, and that is, how do we get payers and policy to shape what we do? There are just a few here. NHS drives funding.
In the U.K., if the NHS wants to do something, it happens, and I will talk to you about that. Dig actually showed you a statistic earlier in the data that showed you there has been an increase in the number of leads in the NHS. We will talk about how we are making that real. In France, some of you will know that, but Macron had a 100% Santé policy, which was teeth, eyes, and ears. Wonderful funding in France at a lower rate, but that policy drives what we do, and how do we maximize that? In Germany, there is great funding for hearing aids, so penetration rates are quite high. How do we maximize that? If we think about EMEA, large aging candidate base, low penetration of cochlear implantation, and some good policy initiatives that are starting to help us.
We see a multi-year opportunity with regards to that. It's a complex place. Dig spoke, and he has many times that we work in 180 markets, 72 of those where we work are in EMEA, and Europe, Middle East, and Africa. We have many languages, which creates some interesting complexity. How do we manage that? We have broken our region into six major hubs, so we run this by hubs. If you think about it, of our key markets, really five markets in the developed world matter in EMEA, and we are going to talk about those markets. Really, that's where we are driving most of our activity and most of our investment. Around the region, we do work directly in most markets. We have hybrid in a few and indirect in other.
Similar to Asia Pacific, in the developed markets, the establishment of pediatric pathways are very, very clear. There is very, very good reimbursement, good follow-up, and we are not focused on that in the developed markets, but we are focused on growing adults and seniors. What I am going to show you in the next slides is, how do we get awareness and access and capacity going. In the emerging markets that I do not speak about today, very much in Africa, we are working on just getting things started with universal newborn hearing screening, working with foundations. In the Middle East, we are doing the same. Big opportunities there, high birth rates with high prevalence because of interracial marriage, inter-family marriages and so on, leading to higher rates of hearing loss. Key takeaway, big opportunity, big markets, what are we going to do?
When we think about EMEA, and this is very similar, just in a slightly different process, we think about it from demand, treatment, access, and leading through innovation. I am going to take you through each of those. I do not want to miss out on the fact that as we move towards medicalization, that is going to create, as Brian has shown us, even more opportunity, particularly in developed EMEA, where they are really open to these sorts of changes in the environment.
Let us start with expanding demand. Let us talk about Germany. In Germany, there is about 1 million patients who we believe would benefit from a cochlear implant today who currently do not have one. They just do not get one. Today in Germany, there is no doubt that people are not aware as well as they should be, even though we have that 5% penetration rate.
What we are doing is we are starting to use direct-to-consumer to really help prompt early intervention, and we are doing it in two ways. One of it is on the left there, which is when hearing aids are not enough. If hearing aids are not enough, what do you do? Where do you go? What activity should you take? On the right-hand side, you can see earlier CI. Sometimes the best hearing aid is none at all, is another campaign that we are running to go straight from identification, you have severe to profound hearing loss, to going straight to a CI. What does that mean? In the last rolling 12 months, we have generated 4,000 leads. 700 surgeries have come through those leads. Dig and Stu have both spoken about the dark and the light funnel, or the Cochlear part of the funnel.
If we think about the total number of surgeries we get visibility into Germany from all of the different areas, direct-to-consumer and direct-to-professional, we have visibility to about 25%. On top of the DTC, we do get some DTP. Lots of opportunity here. We are seeing some great momentum in DTP. Very excited also, and you will see a similarity. How do we work with the hearing aid channel? How do we work with the ENT channel to make sure that we can get even better access to patients who would benefit from a cochlear implant? Here is an example from France. You can kind of see identification, information, referral, follow-up. There are lots of things that we are doing in the channel. What are we doing that really makes a difference?
At the beginning of November, we finally agreed with Amplifon to move forward on a program of work we have been thinking about piloting for a while. We identified 2,500 patients on their books, working together, who have severe to profound hearing loss, who currently have a high-powered hearing aid. In France, remember, it is funded, so there are really high rates of high-powered hearing aid 2,500.
In two weeks, we got 700 appointments from people who have high-powered hearing aids to come back in and start their journey onto cochlear implantation. There is no doubt that these activities help. If we keep accelerating the work that we are doing in those channels, we can get more and more patients. We are excited about this. It does not mean we will get 700 surgeries, but it certainly means that we will get more and more awareness and more people into the channel.
What we are doing next in terms of treatment, I think it is really important, and one of the things that we are really passionate about is how many people we train. As we said, there is an aging population, and that also affects our clinicians. We are spending a lot of time in making sure that we have the next generation of rising stars, both in surgical and audiology, and we are doing a lot of work to make sure that we are bringing them through the process.
In the last 12 months, we trained over 450 people in EMEA. I think it is really important because that is the future of how we are going to do treatment. We did over 30 professional education events, and we track and we work with people, and they are starting to understand the benefits of why you would use Nexa, for example. We spoke about this, and Dig showed you this right at the end of his slide early on, which is one of the things, which is how do we free up clinical capacity?
In EMEA, most of the service is done through the public system, and the way that treatment has been going on for years is quite the same. The way we identify patients when they come into the CI clinic, the way surgery is performed, and then each clinic had an aftercare protocol, which was really individualized. Sometimes there was more than 20 follow-ups in the first year. Sometimes there were 29 in one account. We have been working now with 65 different clinics across EMEA to work out how do we use that evidence that Dig showed to bring that down to a more reduced number that still gives the same outcome.
These workshops have happened all around EMEA. We have saved thousands of hours of clinical capacity, and all the accounts, the 65 accounts, are all growing significantly faster than the rest of our accounts, because that time that was spent in aftercare, and we are using Remote Check, we are using Remote Assist as well, is now used in the front end. We are also able to change the capacity that happens in the markets there. We are also working now in January on how do we do this from a surgical perspective. Great example a few years ago in Japan, where we worked with the University of Tokyo, and they were doing two surgeries in the morning, and we worked on them to get to three surgeries in the morning by changing their processes.
So we're taking a similar approach into EMEA and working out how do we now help clinicians think about this differently. We have some really innovative surgeons who are willing to do this, but we've got to work within that government system to do it. This is really helpful because it enables you to do more at the front end. Let's talk a lot about GAMA. I think Stu did a wonderful job to talk about some of the things that are happening based upon the work that we've seen from Brian and others. I want to talk about three things in GAMA. The COACH study you saw from Brian, and that is the study that's going, the randomized study, hearing aids, cochlear implants.
We expect that the study will be closed in February 2027, and we're hoping for the first data to come out of that at the end of the year. This is critical data, as Brian said. Obviously, this is a Cochlear-funded study, but it's done independently, so the timing of these things is really up to the publishing through our partners. This is critical because we're going to have evidence that we can use not only in the U.K., but we can also use all around EMEA and around the world. An interesting side fact, the reason why some of the recruitment took a while is because we actually identified 100 patients who moved to get under the current 80 dB or worse criteria during the process.
It was quite a difficult recruitment because between 70 and 80 dB is a fairly strict criteria, and we actually moved them into traditional criteria and cochlear implantation. The next one is thinking about how do we work in terms of co-developing policy. In our five key markets now, we now have five agencies working with us, and we've done this over the last year. So in Spain, U.K., Germany, France, and Italy, five agencies to help us work with government on designing policy. The U.K. example there is a great one. We used people from the NHS, interested surgeons, audiologists, patients groups, and we came together to build a consensus statement based upon what we already had on a program called Left Unheard. The U.K. numbers, official numbers of cochlear implantations for adults and seniors have gone down for the last three years.
Less people are getting access than ever before. We're now putting submissions into dementia, frailty, and all of the things that governments are talking about in the U.K. We have this small group of individuals who are passionate about getting people from being left unheard to changing policy. The last one there is a really interesting one. In Europe, quite often you need to see an ENT before you get access to reimbursement for hearing aids. In France, that's the case. In Germany, that's the case. So if you want to get access to some reimbursement, you need to go see an ENT. Today, the referral pad doesn't have a criteria for cochlear implantation.
We are working very hard with the ENT society and others, and we are hopeful in the next 18- 24 months that that referral pad will say, "You should be reviewed for a cochlear implant, not just a hearing aid." These are all examples of how we are using government affairs to change policy in a place that is heavily government funded. Let us talk then a little bit about some of the wonderful work we are doing with Nexa. Nexa is really starting to get momentum in EMEA. In Germany, 100% of all the cochlear surgeries done now are using Nexa. There is a better and increasing understanding of the future opportunities that exist, and we are very passionate about that.
You can see the number of things that are coming in terms of we are driving winning brand choice, and we are doing that both through DTC as well as through referrals. This product is really a great opportunity for us to continue to grow our business. Finishing where Stu finished as well is just on Osia. Osia 3, we did not spend much time on it, but Osia 3 answers a lot of questions that our patients have. It has a rechargeable battery. It has better hearing. It has better connectivity, and it also has 65 dB. It is a really interesting product. We are moving through to win back some share. Sentio, through Oticon Medical, you will have seen launched, so we are using that to win back some share. How do I feel about this? The early indicator, we launched this at the beginning of November.
We look at Salesforce a lot. We use that to track what we do. We had 750 individual Osia 3 recognitions in Salesforce in October, which shows us that the early indicator is Osia is being discussed in the market at the rate we would expect. Overall, we are very excited about the future in EMEA. Obviously, the short term, we will keep driving, but the longer term is really working with governments, really working with societies to really help us reengage and ensure that people are not Left Unheard. With that, I am going to pass over to Karen. Thank you.
Good morning. I am Karen O'Driscoll. I have the privilege of leading technology and data here at Cochlear, and I am really excited to have the opportunity to close out the presentations with some information about our technology strategy, the progress that we have made, and the value that this is providing across the organization. Our technology strategy has three layers working together, with cybersecurity protecting all of them. The aim is really simple: drive cost-effective scalability and enable growth. Our core systems provide solid foundations. This includes ERP, our customer platform, and our people platform. It is consolidated, standardized, cloud-based, and cost-effective. This supports back office productivity and cost-effective operations. In the middle there, we have our data and AI platforms. This is really the glue. APIs, data platforms, and our data and AI governance gives teams access to connected data with self-serve access to insights and reusable features.
This has guardrails so that data stays secure and governed. At the top, you can see edge technologies. This is where our investment is now focused. These are data products, automation, and AI agents and apps. They are fast and pretty cost-effective to build. They are secure by design and very close to the business need. They improve efficiency, effectiveness, and also improve our customer experience. Running across every layer are our security tools, procedures, and practices. They protect Cochlear data, our customer data, and also our business operations. They build trust and support regulatory compliance. Together, that is what lets us scale with confidence. This slide shows more of our technology journey and how we have moved from foundations outwards. The headline is that our core systems transformation is substantially complete. I am pleased to say that. Investment is now shifting to edge technologies.
This is where we can drive the biggest gains in efficiency, effectiveness, and customer experience. You can see here a lot of ticks. These are the things that are complete and already delivering value. The rings are what is in progress. The play icons are what is planned in the future. We started at the bottom, and that is because a stable core makes everything else possible. in FY 2024, we delivered Workday for our people platform. In FY 2025, our Salesforce Health Cloud. That includes supporting our customers, recipients, and candidates, but also professionals and referrers that you heard about through all of the presentations. We have also delivered a manufacturing execution system. Our SAP program is well progressed and currently in the user acceptance stage. The result is simplified and standardized processes and lower risk and cost across our enterprise.
You can see that collaboration and quality management systems are planned for refresh in FY 2028 and beyond, but the main work of this layer is now done. The middle layer, as I said, connects everything. We launched our customer experience cloud. We have built a sonar enterprise data platform. We have a secured Amazon walled garden for AI with APIs and our own AI harness and models. These are all now complete. This is what lets teams use data and AI safely and consistently, rather than every project building its own version. The edge technologies, as I said, is now where we are concentrating. In progress today, across this year and next, is work in three areas: our customer experience with our candidate concierge and customer service agents, sales already using Customer 360 and Sales Insights. In engineering and IT, we have software development and IT operations being automated.
Into FY 2028 and beyond, we plan to extend into back office automation, looking at finance, people and culture, and legal, demand and content generation in sales and marketing, and also knowledge and documentation in R&D, and of course, manufacturing automation. Underneath all of this is our continuous security program, protecting platforms and data. Unfortunately, this is not a one-off project, and it runs across every year and every layer. This sequence is deliberate. A stable core first, a connecting platform, and then edge technologies on top. With the foundations built, we can move much faster at the edge with confidence. The timing of the planned items here is indicative, but the direction is clear. The question we hear most about AI is, how do you encourage people to innovate without losing control? This slide is our answer. It is an ecosystem that balances the two.
AI tools sit on top of governance layer and inside our walled garden, so we can scale AI across the business safely and under control. At the top are the tools people actually use, and we have matched the tools to the job. We built our own Cochlear AI assistant and are now deploying Amazon Quick as the enterprise desktop AI for employees. This means everybody can boost their productivity and can experiment in a safe and controlled way. We also have AI for our high-end innovators, the people really pushing what is possible. GitHub Copilot is our engineering platform for our software engineers across the organization. Each one of these has its own guardrails and safety controls built in, and all of them draw on the same shared governed AI services. The second layer is what keeps it safe.
AI models and agents can change over time and can act with some autonomy. We need to manage them the same way as we manage people. We are deploying observability, meaning we can monitor and audit what AI is doing. Control sets the rules for access and spend, and which model is used for which task. Identity gives every agent a managed identity, so it interacts with our systems in a contained and accountable way.
The third layer is where models actually live, in our walled garden. Our agents work with clear boundaries that are enforced at the infrastructure level. There are shared services such as tools, skills, and prompts that every domain uses. Each domain has its own space for its agents, so they can be set up by geography, business ownership, or use case. So in practice, this really means three things. All employees can use AI to experiment.
Our prioritization process makes sure that the highest value use cases get developed. Our experienced engineering teams build and deploy AI using approved tools and secure guardrails. So we are not choosing between innovation and control. The structure is what gives us both. People are free to experiment, and the business is protected. That is how we will scale AI quickly and with confidence. This slide is really about proof of value. AI is already delivering measurable results for us, and the next 12 months are about scaling it further. Our transformation pods are driving gains in productivity, in decision-making, and in conversion. AI here in Cochlear is not a single tool. It will support surgeons, hearing health professionals, candidates, referrers, and our own employees.
We are delivering that through five capabilities: the AI brain, which is knowledge, our concierge assistant, chat, and of course, Jan mentioned AI being embedded in our products. So let me start with what has already been delivered. Our sales assistant enables real-time voice updates that improve customer insights and can recommend next best actions. The automation means much less admin and much more selling time. The candidate AI concierge cuts admin and speeds up the early stages of experience and the journey. It prioritizes candidates by how ready they are to move forward. Then there are some numbers. Software development AI automation has, on average, increased our code development velocity by around 30%.
Our insurance agent has delivered more than a 30% productivity improvement in reimbursement claim triage in the U.S., and order status assistance has deflected more than 50% of upgrade calls, freeing up our teams to focus on calls that actually need a person. The next 12 months builds on all of this, with our sales assistant moving to real-time coaching and further productivity gains. For candidates, we plan to provide personalized information in real time, which should reduce the time to conversion and give our teams more time with the candidates who are most ready. In the U.S., we already have insurance claims supported with AI, and we plan to extend even further for faster processing and less manual effort.
In customer service, we are aiming for more than half of the calls to be either supported by AI chat or our AI knowledge brain, giving customers self-service and our teams a huge productivity lift. I think the pattern is clear. We have moved from pilots to measurable outcomes, and we are now scaling them. As the footnote says, the planned benefits are targets, but the delivered results show that we already have a good track record. To wrap this up, I am just going to give you a taster of some of the tech we are working with. You can see more of this in the booths outside of this session.
We can now give customers access to curated knowledge through digital avatars. Without providing medical advice, there is still a lot of information people need access to be able to be comfortable with CI as a treatment option. With these avatars, they can talk naturally in speech or in text, and in their own language. I will show you a quick two-minute demonstration, which really just scratches the surface of the opportunity we have to federate and make accessible the huge amount of knowledge and information we have. Can we play?
[Presentation]
So that's information available at any time in the customer's own language from approved content. It's one way that we can scale our impact without scaling the effort in the same way. Thank you for your time. I'll pass back to Dig.
Okay. Thanks, Karen. We're at the end of the presentation, so in just a minute, we'll move to questions. Just wanted to try to wrap up. We've focused very much on developed markets today for the obvious reason, it being nearly 80% of our revenue, and the growth in cochlear implants in the developed market is a critical driver of our overall growth and value. Hopefully, you can see from the strategies that we're employing for growth, around medicalization and building towards referrals and lifting awareness, combined with our technology strategy, our product strategy, and how, when we look at the Nexa platform and DEE and TIKI, how that integrates into our growth programs to address each of the barriers to referral and each of the barriers that potential patients face as they go through their hearing journey.
It's the combination of those things that give us confidence that not only can we have good, strong growth into the future, but that growth can be more resilient to economic conditions because of the work that we're doing to medicalize with partners outside. Because what we've seen, one of the things that's been obvious when we look at results in other MedTech companies over the last year, is therapies that are more medicalized have been far more resistant to the broader economic conditions. So that's the overview of our strategy for developed markets. There's a number of things we haven't talked about today. We just touched on Acoustics, and that's performing well, the importance of upgrades. It was very important, we thought, for Karen to present.
We have spent a lot of money over the last six years replacing our core platforms, but hopefully you got a taste today of the value that we can now realize, which there is no way we could have done if we had our old core platforms, if we had the old data structures or lack of data structure, lack of process consistency across the organization. What that enables in terms of us being able to now scale with the benefits of these platforms, but then AI on top of that, will help fund our investment in growth and R&D, but also help drive growth through some of these things like the AI concierge. Okay, with that, let's move to questions. All of the presenters come up, and Sarah Thom, our CFO, will join as well. Let's start on the questions.
Hi. Chris Cooper, JPMorgan. Dig, firstly on TIKI, you mentioned the need to deliver hearing outcomes that are at least as effective as with the current platforms. How are you defining hearing outcomes? Is that sheer decibels, or are you incorporating 24/7 hearing and cognitive decline and other factors?
So yeah, good question, and there will be a few different ways to do that. Jan, you want to talk a little bit more about this, but with the TIKI, there will be, for our system, there will be hearing without a processor, and there will be hearing with a processor, which will be better for some people in the noisiest environments. But Jan, do you want to talk a bit about just what we're seeing in terms of the performance?
Yeah. Does the microphone work? Yes. Yeah, so first of all, as you saw in the presentation, I think it's in general important that we broaden the definition of hearing outcomes from testing in the booth to real-world hearing outcomes. That includes listening effort, that includes music. It also includes the fact that we want to hear 24/7. If any one of you would take your hearing away for 12 hours a day, I think you would agree that it's deteriorating your hearing outcomes.
So if we give people 24/7 hearing, or the option to hear 24/7, absolutely should be part of hearing outcomes. Now, actually, what we see or what people get through their totally implantable device is that in quiet and even in noisy situations where the noise is coming from the same location as the speech, the results that we get with TIKI are very close, if not the same, as with their external hearing.
Where there is a difference if the noise comes from around you, that's where the external device still has a benefit because it gives you directionality and can suppress noise sources around you. Also, if we think about DNN, the opportunity to use AI in the future, that also will be made available to the external components. There's still a value in that external device to give you some extra capabilities in terms of hearing in very difficult situations, but the TIKI in itself is already doing a fantastic job giving you excellent hearing.
Brian, from a clinical perspective.
Yeah. It's always one of the interesting pieces about TIKI, right? Because it's often more about a CNC word score or a sentence score. To Jan's point, what patients are always clamoring for is a return to the life they had before, right? They don't want to fiddle with externals. They don't want to have to worry about their devices. They just want to get on with their lives.
For the first time, and we've seen it going all the way back to 2005 in the first generation TIKIs that we got, where even when that body noise was quite loud in many of those cases, the patients were thrilled just to be able to engage back in the way that they remember their life being. The results are fairly amazing, as Jan was just talking about, with even in a noisy environment, with someone talking in front of you or in quiet, we're getting equivalent hearing performance. But the patients are really thrilled by having 24/7 hearing, even if they're giving up a little bit of performance in those really challenging background noise situations.
Okay. Thank you.
Just one for Stu, if you do not mind as well, quickly. So, very significant increase in the reimbursed market in China. Are you beginning yet to see any sort of tapering or normalization of the volume growth, or should we be thinking about double-digit volumes for the medium term at least in China?
Certainly do not want to be giving a trading update. We saw big growth in 2026, and that was the first year we had really significant VBP impact. Time will tell whether that is an ongoing thing or that is going to moderate after 2026.
David Low from UBS. Dig, we saw the ambition, use of the word ambition and the 10% growth rate in profits. It is a bit of a change from the revenue growth and margin guidance that you have given in the past. Can I get you to elaborate a little?
Yeah. Yes.
Sorry, one, if you could just touch on the implications of the competitors having fully implantables over the next few years and how that might play.
Okay. First of all, on the margin profile. We have said for a while now what we would aim to do is grow the top line at 10%, 75% gross margin, 18% net margin. Effectively, that is saying we intend to grow the net profit at 10%. In terms of the setup, it is no different. As we talked about with the growth of China and FX, the gross margin is lower than the 75%. We have focused therefore on the net margin. Really, it is not changing what we said in the past, it is perhaps simplifying it. We do see, to get that over time, we have got to get revenue growth at that level as well, and we think that that is eminently achievable as these strategies come into effect and as the technology plan rolls out and these products get approved.
In terms of the impact of competitors having TIKI approved before us, which obviously MED-EL has a CE mark in Europe, what we are seeing at the moment is no significant impact on our sales. The price that they have on it is very high, and that means it will not go through the reimbursed systems. With any TIKI, with any new technology, there is a time to scale it. There is more, as Jan talked about, there is a lot more complex technology in a TIKI. It is why we have taken time to get there, because the more technology you put in, the more risk there is, and time to run down that risk is important. We are not seeing at this stage, I am not seeing an impact at all at this stage. Obviously, we are having both pivotal studies going in Europe and in the U.S.
That then leads to a regulatory submission, and if the data is sufficiently good, regulatory approval. We don't think that we're going to be too far behind, but as we've always, we're not going to put a date on when that could be. I think it is very much about how a TIKI is launched. What we've not seen, and maybe perhaps you can comment on this, I don't think we've seen any impact even on surgical holds at any significant level from MED-EL launch.
No, at this stage, we've seen no surgical holds. Certainly, there's been a lot of noise in the market, as you can imagine. But we have not seen large numbers of cases being done. MED-EL's being very open about what cases are occurring where. So that's available publicly, but they're very noisy in the consumer market. As Dig said, the price, they've kept the price at a very high level. So clearly, cautiously is their approach from the way we see it.
As I outlined before, the whole point of a TIKI is mass market adoption, and there's a number of criteria and characteristics to get right for that to happen. We're confident we are doing that, and then there is a path to lead to that ramp up over time.
Sorry, one quick follow-up on the topic you've raised. Could you talk about the price? I mean, it's been a little hard for me to pin down exactly what they've priced it at.
I won't talk about MED-EL's price. They can do that. But it's a multiple of current reimbursement. Obviously, not going to talk about our price. That's, A, we're not there yet, and B, our competitors would love to know what we're thinking.
Yeah. Hi. Andrew Paine at CLSA over here. You're obviously focused on the referral pathways. How do you have visibility that you're not just shifting that from the self-navigated into the pathways where you have visibility, as opposed to trying to increase penetration?
Yeah. Great question. Over time, that's what has happened. Our Cochlear support, whether they're professional referrals or DTC, is pulling people from the self-navigated pathway into our pathway. That has worked well for us, as we've seen, 25%-35% of our sales across some of their leading markets. But the whole point of doing the opening up the self-navigator one is it's not scalable to keep pulling people through. So what we're doing in the U.S., where we're most advanced with this pilot, is what we're aiming to do is to educate these referrers to refer directly to the Cochlear implant clinic, not refer onto us. So we've already got a network that refer onto us, but then there's our cost and time to get there. What we want is the direct referral. So we're actually running these as quite separate.
If there's clinics in there who really want to refer to us, then we will obviously take that. But what we're seeing is there is an interest actually to refer direct. That's what happens again. Think about a medicalized condition, the referral is direct to another professional. It's not through a manufacturer. So I hope that answers the question, but we see the distinction, and we're deliberately and actually trying to activate that channel so we're not involved.
Steve Wheen from Jarden.
Thanks.
Dig, just wanted to follow up and clarify on the TIKI. Cochlear has the most recognized and perhaps the best brand in the market. A lot of anticipation around your own efforts in TIKI. Are you seeing deferrals for your own leads as they wait for your launch of the TIKI?
No, we are not. The one instance where there are some deferring, you have some employees who are deferring, who have Cochlear on one conventional implant on one side and one TIKI as a bilateral option. Stu and AB, Brian, you will be seeing clinically. Are you doing anything?
Yeah. No, patients ask about it, and they obviously were aware of the launch. Then you get into conversation. There are high switching costs for this, right? You want to have, what is the correct device? What is the best device for me to be able to implant in? When you think about what do you really want out of a TIKI, you want surgical simplification where surgery does not take much longer, you want great battery life, and you want a great microphone that is going to give you very good noise cancellation for your body noise. I think that is the place that we are clearly going to be in the lead with our product. I think the other piece, which sometimes gets overlooked, is for the majority of the day, these patients are not going to be wearing externals.
You think about the Nexa platform that Jan was talking about earlier. The only ability to be able to upgrade your implantable TIKI in your internal device is going to be if it is on a Nexa upgradable platform. If it is not, you are stuck with a legacy technology that you have got in there that can never be upgraded. An easy conversation to have with the patient, and they understand the value proposition, and we have not had anybody hold.
Stu, AB, are you hearing anything on-
Certainly not seeing holds. Number one question I get from professionals is, when are we launching ours? And they are able to counsel people, as Brian has shown and explained, on making sure they address their hearing loss now because of the potential risks if they wait. So we have not seen a major issue yet.
Yeah, same. Nothing material yet.
Could I just follow up with the Nexa? Was the launch of the Nexa a bit of a precursor to the TIKI because you can use that data perhaps to fast-track the approval of the TIKI? Is there any sort of advantage around that? Then maybe just on that, when you did launch the Nexa, it didn't come with the electrocochleography application. Is that now in SmartNav?
Okay.
Thank you.
I'll let Jan answer that second one. The first part of the question, the key value from Nexa as a precursor to TIKI is us getting experience with the platform and seeing the stability of the platform. We've had outstanding reliability for the Nexa implant now, for two years in. As I said earlier, when you put new technology or more technology in an implant, there is a risk. We've had outstanding performance. That de-risks the TIKI launch because it's largely the same electronics. So it's more about risk than it is about data. Jan, do you want to talk about the ECochG and-
ECochG, yes.
and any insight on data you have?
First of all, maybe for everyone, ECochG is also another diagnostic method that some clinicians use. At the moment, it is available through our research tools, not through our routine clinical tool called Nucleus SmartNav. That is the same for Nexa. At the moment, it is accessible for those that want to use that. The reason why we have not moved that over yet to Nucleus SmartNav is because we still are trying to understand what is the actual clinical benefit of that.
There is definitely a level of interest in it. Over time, we expect to bring ECochG to SmartNav, but we are very cautious. We designed SmartNav as a routine clinical tool, not as a research vehicle. We have our research software used as a nursery area, and when these algorithms have matured enough, then we will transfer them to SmartNav, provided there is also good clinical benefits there for the majority of cases.
That is part of this dilemma that we see and you hear about is, there are a number of clinics, important clinics, who want to do a lot of research. The scaling of the therapy requires really efficient surgery and aftercare processes. We have to deliver that efficiency at the same time as delivering research, but I think if we put the two together, it is possibly suboptimal on both.
Hi, thanks. Davin Thillainathan, Goldman Sachs. Thanks, Dig. Thanks, team. Just wanted to understand the year-to-date trading update and link that to what we have learned today as well. The comments about developed markets, mid-single-digit volume growth, could you give us a sense of how the U.S. is going, given you are doing a lot there to lift medical referrals? Separate to that as well, your market share, given the Nexa benefits, have you seen a lift in market share in that number as well?
Okay, I can say, perhaps repeat what I said earlier. First of all, I said about the referrals work that we are doing in the U.S., that is longer dated than the first four months of this year. We are into 10 cities, we have got people on the ground, we are learning from it. This is about building referrals into the future rather than in the first quarter of the year. We are, as I have said, in Europe, we are regaining some share in Europe. We also are not seeing in Europe the continuation of that confluence of factors, so we are getting that recovery in Europe. In the U.S., as we are seeing from the MedTech Q3 reports, there is a continuation on insurance denials, there is continuation on poor economic conditions or consumer pressure. That said, our U.S. business is performing in line with our expectations.
Yeah. Hi, Dig. It is Dave Bailey from Morgan Stanley. Some comments there around DTC, more conversions of referrals, and things like that. My question is, with the current macro environment we are seeing at the moment around capacity funding, if those things were to pick up, do you think the macro environment is conducive to getting more people implanted at this point?
I think the macro environment is certainly still difficult. What we see is that through the Cochlear-supported part of the funnel, that continues to grow. We are making it, that shows, as I said earlier, where there is our intervention, where people get the right information at the right time, they see the need to treat, and they go ahead with treatment. The purpose of our strategy is to make us more immune to conditions. We have not seen that impact of conditions in the past, but perhaps they are more extreme now, and that adult segment is a bigger part of the sales.
If those referrals start to pick up a little bit, or conversions start to come through, you do not see constraints around the surgical capacity or the funding environment that would mean that there would be people that could not actually get those implants?
Okay. There is enough capacity in the system for sales to grow. There are always bottlenecks in various places. AB mentioned the U.K., where actually the surgery volume was down last year on this year, but wait lists are up. Some of the Australian states have wait lists going up. But there is enough capacity out there in the right places, but that is why we have got to work to expand it.
And one for Jan. Maybe just thinking about shorter perimodiolar electrode arrays versus long lateral wall. It was not necessarily touched on today, but just the performance of those two. I mean, there has been some marketing out there maybe that longer Cochlears need a longer electrode array. Just wondering if the shorter perimodiolar give the same sort of performance?
Yeah. So, maybe for the audience, there are basically two types of electrodes, lateral wall that sit on the outside, if you want, the outside track of the cochlea, and perimodiolar electrodes. So first of all, the cochlea has much less variability on the inner track than on the outer track. So for lateral wall electrodes, there is a philosophy that you want to optimize that length depending on the size of the cochlea, which is one of the, if you want, anatomical parameters. Our conclusion is the much bigger influence on outcomes is that neural health. So whether the electrode is one or 2 mm longer, it has 50 degree more angle insertion depth, is much less important than understanding the neural health and then optimize for that.
Now, there is always opportunity for us to look with a sort of deeper perimodiolar electrode, eventually be better, get 50 degrees angle insertion depth more would be maybe nice. We do not think it is actually a dominant factor. Actually, none of the evidence that is out there would support it either. The evidence that is out there is that neural health is the dominant factor in terms of outcomes. We know there is a good story there from one of our competitors, but the data does not really hold up. That is what we are doing with Nexa, using unique ability of Nexa to create that unique fingerprint of the individual and link that with outcomes and then optimize it for that individual.
Yeah, just to add up to that, the data is fairly clear. Your cochlea is a snail shell. The center of the snail shell is your modiolus, which is where the nerves are that you are actually trying to stimulate. The goal is, how do we stimulate the maximum number of nerves and be as least destructive as possible in the process? It is a trade-off. That lateral wall that Jan was just talking about, it is a racetrack. If you go on the outer wall, it is a much longer journey than if you take on the inner loop. If you look at the percentage of those nerve cells that you stimulate, a 15.5 mm insertion of a perimodiolar equals a 30 mm insertion of a lateral wall. They both stimulate 88% of the spiral ganglion cells.
What we know is that lateral wall electrode is rubbing against the lateral wall as we go, causes a bunch of injury, which leads to fibrosis, why we are looking at the dexamethasone, and the perimodiolar stays in the proper location, avoids the basilar membrane, which leads to as good hearing preservation with much less fibrotic response. So you get the best of both worlds.
Maybe to add one more thing to that, we are also adding technology in SmartNav to actually help surgeons even more, even better placing the perimodiolar electrode. Because at the moment, it is a bit blind. You insert, you do not know exactly where it ends up, but we are far advanced with a technology that can come through SmartNav to help optimize the placement of that perimodiolar electrode to make sure that that electrode is also effectively placed perimodiolar. Because often it is a bit over-inserted, and that is something that we seek to assist physicians with the next iteration of SmartNav.
Andrew.
Andrew Goodsall from MST. Just, I guess, taking that a step further to focus stimulation, just trying to understand the pathway to getting that turned on, I guess, as a program that is available, and just the capability to switch that on and off where you do have dead zones, I guess, in the spiral ganglion.
Yeah. The data that we have showed so far came from studies that we had started actually prior to the release of Nexa. Since then, of course, we have now many more patients out there that have a Nexa device, a great interest of academic centers to work with us. We have far progressed to developing research tools that we can provide more broadly to the research community, both from a diagnostic perspective, but we are also progressing the focus stimulation from the sound coding perspective.
At the moment, we are ready to start a large study on neural health with 200 patients around the world, and we are planning another study with 40 patients on using focus stimulation for sound processing purposes. Absolutely progressing that. But as you see, we have a lot of things on at the moment, a lot of balls to juggle, but I hope you can see also how it all amplifies and comes together as these technologies progress simultaneously.
Just a question for AB and Stu, just a lot of comments around caps in terms of surgical caps, and it sort of follows on from David's question. How difficult is it to, I guess, break through those caps or get greater funding so the caps are moved up?
There's kind of two things I think that we can work on. The first one is we're trying to give more capacity, as I mentioned, because sometimes it's not really the cap, it's how many they can get done in a clinic because of capacity, so we work on that area. The second area is, which is why we've got these five government affairs agencies, is to work on making sure that we can remove some of those caps. That is hard work, but it's important work. Left Unheard, for example, in the U.K. is an example of the work we're doing. It takes time, focus, but we're confident with our partners over time we will get some success.
Yeah, same thing. I think it's probably more, the thing about Australia, it's probably more cap-related and less so surgical efficiency. But it's possible. It takes effort on multiple fronts. You're working with the provider, you're working with the payer, and you're typically having to build a backlog as well at the same time to try and increase the pressure. It tends to be a longer-term game, and the ability to predict exactly when it's going to break is low.
Agreed.
Also, this is a forever game, right? The therapy is much bigger than it was 20 years ago, much bigger than it was 10 years ago, and we were talking about capacity constraints back then as well. We work away, and we chip away, and it opens up, and it will go on.
Thank you.
Sacha Krien, Evans & Partners. Hi, Dig. Just wondering if you can share a bit about what you see as the shape of FY 2027. We have seen some pretty solid mid-single-digit implant growth in the first four months. I assume there is a bit of price on top of that with what you have taken with the Nexa. Then you are talking about, I think, modest developed market growth across the years. I am just wondering what changes over the next eight months.
Yeah, not to say too much more than we have said in our guidance, because I think we have laid those things out. Just on the price point, most of the price increase we got in Nexa, we got early last year, so there is not a great increment from a price perspective in our numbers this year. It is about volume growth. Otherwise, I think what we have already said, it is good to have mid-single digit so far. We are expecting growth through the year in the CI. We have said we expect some growth, we said that earlier on the upgrades, particularly out of the U.S., to be part of this. Acoustics is growing too, so we expect to see growth across each of the revenue lines.
Next question. We did not hear a lot about the retail channel in today's presentation. There is a lot of consolidation happening there. You have talked about that being a bit soft historically. Some of the numbers coming through from those hearing aid companies are actually pretty solid, so I am just wondering what trends you are seeing there that you can share.
I think, yeah, so it is good to see the hearing aid volumes picking up. I think that is definitely positive. It is too early to say is that going to have a flow-on impact for us. AB talked about what we are doing with Amplifon in France, so there is definitely opportunity to work with the hearing aid channel. Similarly, in parts of Asia, particularly in Australia, we work on referrals there too. So we see, we will keep working with that channel, and if the volumes pick up, I think that is a good thing overall for us.
Okay, thank you.
Hi. Hi, it's Craig Wong-Pan from RBC. Just on the Amplifon agreement, sounds like a really good agreement for you, but just wanted to understand if there's any benefits for Amplifon from that.
I'm not sure how much you can say commercially.
I can't really talk about the commercial arrangement we have with Amplifon, but I will say this is a pilot, and Amplifon has a large international network, as we know, so we're going through a pilot phase. It's early days, and I can't talk about that arrangement.
Okay. Second question, just on the global staging collaboration. Just wanted to understand rough timing for potentially when that could be completed.
At this stage, we want to go through the French pilot, and we are working very closely on that pilot. In time, once we get the data from that pilot, again, we have only had a couple of weeks in, we will be able to share more.
Sorry, I meant the, yeah, the global collaboration.
Oh, sorry.
The ICD.
The ICD codes, okay.
Yep. So, like everything else, it's always a little bit nebulous, but the process is about a three-year process to go through this. There's a bunch of work streams that have to happen contemporaneously. The staging system, which is going on right now with Macquarie and Mayo, that has to go through the WHO and then get ICD-11 coding. So the first step of that is the FY 2027, to submit that along with the multiple other comorbidities. That has been submitted already for publication, and the early first two work packages are now sitting with the WHO already. So we should see progress over the next year or two.
Thanks. Saul Barrenjoey. Dig, two questions. You haven't mentioned growth of emerging markets at all today. I was wondering if you could touch on, has anything changed since last year, and is it an issue around volatility regarding tenders? Just some commentary around emerging markets.
Yeah, we haven't talked about, apart from Stu talking to China, we haven't done it today just because we're forward-focused on where the growth opportunity is. Look, in terms of emerging markets overall, it continues to be a good long-run growth opportunity, and we've seen strong growth. We've always said that growth is more volatile than developed market growth. There are still challenges in the Middle East, obviously, but otherwise, I think the emerging markets are performing largely as we expected. Certainly from an FY 2027 perspective, it's included in our guidance. Over the long run, a good opportunity for stronger growth.
Thanks. Then just following up on the TIKI from an economics perspective as it relates to Cochlear specifically, granted you're not willing to talk to price, but from a reimbursement perspective, is the assumption here generally payers are not going to pay more for something that effectively is arguably aesthetics? Granted, you get the 24/7 hearing, sure, but how they're going to look at this, and then on top of that, how does it change the economics of an upgrade cycle as well?
Yeah.
Do you get an upgrade every five years with a TIKI? Is it more about internal upgrades, and would that be reimbursed?
Yeah, so we can talk a little bit about this. I can't go too far. As I said, to get mass adoption, you're going to have to work within the constraints of the healthcare systems. That probably means broadly within the constraints of existing reimbursement. That said, there is room within existing reimbursement in many countries. It also means we may not take TIKI to every country, right, if the reimbursement isn't at the right level. But we'll have more to say as we get closer, but we can see a path here. From the upgrade perspective, so for the way our TIKI works is that the external component is both a hearing booster and a charger. Right, so the battery needs to be charged every day or so. As Jan said earlier, in certain situations, people will want the external to hear better.
We see this in the feasibility studies that we have done. We see a range of the amounts of time each day that people wear the external. I suspect as we get into this further, I bet we will see that correlates with neural health. Poorer neural health outcomes are tougher and more likely to want support. That said, that external is an integral part of the system, and actually does more than the past because of that charging. It will wear out over time, so there is still an upgrade path for the externals with the TIKI system under the way that we have configured our system. In terms of upgrades to the technology in the implant, there is potential there, but we have not progressed that particularly far. We know what we can do, but we have not progressed it from a commercial perspective at this stage.
Dig, if I can maybe challenge the note is that it is merely cosmetic benefits. Just an anecdote from actually one of the patients in the study. We heard last week from an audiologist that is in the study, elderly lady decided to get a TIKI because she is a cochlear implant user, the TIKI on the second side in this case, because normally she does not hear at night. What happened a few months before, her husband went to the bathroom, fell over, was on the ground for the rest of the night. So there is a real functional benefit of the ability to hear beyond the time you have an external processor.
It is our role to help also payers understand that yes, the initial motivation may be cosmetic, but if you talk to the recipients, they all say, "This is not about cosmetics." Because that is where we started as well. But talk to any Cochlear TIKI recipient, and they will challenge that it is just a cosmetic benefit. That is our role to explain that also to payers. That is what we do in the studies. Maybe Brian can talk to that in terms of the data we are collecting.
Yeah. We have active work streams right now collecting real-world evidence, patient-reported outcomes, health economic research with validated instruments because it is beyond the hearing test. But if you remember back to one of the studies that I presented, there was Julia Sarant out of Melbourne looking at cognitive decline wearing a cochlear implant versus a hearing aid.
One of the key findings on her study was if you wore the implant for longer than 14 hours a day, you actually saw the benefit at 18 months, where if you did not have it for 14 hours a day, it took you three years to see the same benefit. It is one of the biggest differences we will see with the TIKI implant is how many more hours per day you have access to sound. And with all the evidence coming out now showing the diminishing cognitive impact of the hearing loss with the longer you are wearing the implant, that is a very compelling argument as well from a payer standpoint.
Any more questions? We have a few more minutes. I think we are there. Okay. David has one more. We will be around afterwards as well.
Thanks, Dig. I mean, on the same topic, I do get a lot of questions about the longevity of the battery and what happens when the battery runs out. I think if you could just address that.
Yeah. Do you want to take that, Jan?
Yeah. First of all, we've designed the TIKI that it can be used with an external device, even at the point where the battery no longer gives you meaningful autonomy. It's like with your iPhone, yeah? It takes a long time before your iPhone just completely stops working. The same will be with the TIKI. We do expect, depending on usage patterns, that people get at least 15 years of useful life out of their totally implantable functionality.
But it will depend also very much on personal usage patterns and the like. Also, we have to acknowledge we're still learning a lot. We are cycling these batteries and really testing them, but we're still continuing to evolve that. But knowing that you can always fall back to, worst case, you could say TIKI becomes an XR device, yeah, after 15 years. From that perspective, I think that people shouldn't be too worried about that aspect.
Yeah, Dig, David again. Just on this topic again. Thinking about a TIKI, you mentioned mass market. Do you think that provides a step up in growth? Some of the feedback you get is people are waiting for other ear, or they've got one.
Yeah.
Other ear is maybe going to put something else in there. Do you think that's an opportunity plus as well as getting more people into the system? Do you think a TIKI is an inflection in terms of growth rates going forward?
TIKI certainly has the potential to lift the growth rate. As we talked, it's one of the significant barriers along the way, is visibility and this inconvenience of being able to hear all the time. Market research shows more people are going to be interested. Our clinical studies, the speed at which they recruited shows there is genuinely strong interest in a TIKI. That's why we've got to get the surgery time right, which we think we've done, the programming time, and the commercial aspects right so that it is there for broader adoption. We think that should definitely underpin growth and hopefully uplift the rate of growth. Okay. Let's wrap up there. Thank you all for coming along. We will all be around outside afterwards.
I've also got Sabina Sopov, who's our Chief People Officer, Greg Bodkin, who heads our Global Supply Chain, and Rob McGrory, who's our Chief Legal Counsel. So we've got a lot of the executive team here. Lunch is available in the Taylor Room. There will be people outside to show you where the Taylor Room is. We'll be around to chat if you want to. There is a manufacturing tour that's going to start in a minute and 20 seconds in the foyer. We could probably hold that for a few minutes to let you get out and get some lunch as well. Maybe we'll probably go in a couple of groups anyway, I suspect. Thank you all for coming along. Thank you for those who've attended online.